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ABSTRACT 
Patients with head and neck cancer may be at increased risk for depression diagnosis when 
compared to other cancer sites, both before and after their cancer diagnosis. Behavioral risk 
factors for head and neck cancers, including tobacco and alcohol use, may be indicative of 
depression before cancer diagnosis. Further, head and neck cancers and their treatments can cause 
serious morbidity among patients, including physical disfigurement and loss of function. 
Additionally, these cancers are often accompanied by social stigma, personal shame, and guilt. 
While there is a significant body of research examining depression in this cancer population, 
there are still several gaps in the existing literature.  
This dissertation explores the relationship between depression and head and neck cancer. 
Utilizing SEER-Medicare data, this research examines the rates of depression in the elderly adult 
head and neck cancer population, the influence that depression has on stage and survival, and the 
associations between radiation treatment side-effects and depression diagnosis. The results of the 
studies included in this dissertation may assist in guiding interventions for depression prevention 
and management in this population, and in improving cancer outcomes and quality of life for 
head and neck cancer patients.
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CHAPTER I 
OVERVIEW OF HEAD AND NECK CANCER 
What Is Head and Neck Cancer?  
Head and neck cancers (HNC) are malignancies of the upper aerodigestive tract and 
include areas of the body such as oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx 
(1; 2). According to a recent GLOBOCAN report by the International Agency for Research on 
Cancer, in 2008 HNC was the seventh most common cancer in the world (1; 3). Though often 
grouped together, HNCs are a relatively heterogeneous group of cancers, affecting different parts 
of the body and physical function.  
HNCs can have significant effects on morbidity and mortality of patients, as well as their 
quality of life and well-being. In this dissertation, we will first examine this disease and its 
treatments in order to better understand how HNC can affect those diagnosed. HNCs can be 
grouped into sub-categories based on location in the body as well as specific cancer type. In the 
subsequent sections, we will describe the following groups of HNCs in more detail: Oral cavity 
and oropharyngeal cancers, nasopharyngeal cancers, and laryngeal and hypopharyngeal cancers. 
Oral cavity and oropharyngeal cancers. The oral cavity includes the mucosal lining of 
the lips, buccal mucosa, retromolar trigone, alveolar ridges, the anterior tongue, floor of the 
mouth, and the hard palate (4). The oropharynx includes the posterior third of the tongue, the soft 
palate and uvula, tonsils, and the upper part of the posterior pharyngeal wall (4). The oral cavity 
and oropharynx help in breathing, talking, eating, chewing, and swallowing, while salivary glands 
produce saliva that aids in food digestion (5).   
Different cancers can develop from the various cells in the oral cavity and oropharynx. 
Squamous cell carcinomas make up around 90% of cancer in these areas of the body (4). 
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However, other types, including lymphomas, adenocarcinoma of the salivary glands, and 
malignant melanomas can also occur (4). Based on national estimates, approximately 1.1% of 
males and females in the United States (US) will receive a diagnosis of oral or pharynx cancer 
during their lifetime (6). In 2015 alone, it is estimated that there were over 45, 000 new cases of 
oral cavity and pharynx cancer nationally (7). 
Nasopharyngeal cancer. The nasopharynx is the portion of the pharynx located behind 
the nasal cavities located behind the nose, just above the oropharynx (8). The nasopharynx serves 
as a passage for air into the body (9). 
Nasopharyngeal carcinomas (NPC) are the most common malignancies of the 
nasopharynx, and arise in the epithelial cells and include squamous cell carcinomas, non-
keratinizing carcinomas, and undifferentiated carcinomas (10; 11). Other types of cancers that can 
occur in the nasopharynx include lymphomas and adenocarcinoma and adenoid cystic carcinomas 
(12). 
NPC is much more commonly found in certain parts of Asia and Africa, and tends to 
afflict men more than women (10). In the US, NPC is relatively uncommon, representing an 
estimated 1 in every 100,000 cases of cancer, compared to 25 in every 100,000 cases in parts of 
China (13). 
Laryngeal and hypopharyngeal cancer. The larynx, or voice box, is the opening into 
the trachea from the pharynx and functions in respiration, swallowing, and speech (14). The 
hypopharynx, which makes up the lower region of the pharynx, is located just above the larynx 
and helps in respiration (15). As with other cancers of the head and neck, the majority of 
laryngeal and hypopharyngeal cancers are squamous cell carcinomas (16; 17). However, other 
types, such as adenocarcinomas, may also occur (17). 
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In 2015, there is estimated to be over 13,500 new cases of laryngeal cancer in the United 
States, and that there will be approximately 3,400 new cases of pharynx cancer that will start in 
the hypopharynx (7; 18). The rates of laryngeal cancer have been declining in recent years due to 
the reduction of smoking in the US population (19). 
Epidemiology of Head and Neck Cancer  
Worldwide, there is variation in the rates of the disease between populations. For men in 
developed countries, the age standardized rates for oral cavity, pharynx, and larynx cancers range 
from 5.1-7.9 in more developed regions, compared to 3.4-5.7 in less developed regions (20). For 
females in more developed regions, the age standardized rates of these cancers ranges from 0.7-
2.4, compared to 0.6-3.5 in less developed regions (20). 
Though relatively rare in the US, the burden of HNC is still significant.  It is estimated 
that there will be nearly 60,000 new cancer cases of oral cavity, pharynx, and larynx cancers 
combined, with over 43,000 of these new cases in males and nearly 16,000 in females (7). 
Combined, these cancers will be associated with over 12,000 deaths (7). Further, HNC carries a 
significant financial burden, with the estimated direct medical costs in the US for HNC patients 
was over $3.6 billion in 2010, with nearly equal indirect costs associated with factors such as 
work loss in these patients (21). 
In the US, the rates of certain HNCs have been on the decline in recent years, while other 
HNCs have remained steady or are on the rise.  For instance, cancer of the larynx has been 
declining by 2.4% annually over the last decade (22), likely due to decreases in tobacco use. 
However, oropharyngeal cancers have shown increases in recent decades, which is thought to be 
associated with human papillomavirus (HPV) in the population (23; 24). Though improvement in 
HNC survival has been seen in recent years (25), the survival of HNC remains low, with five-year 
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survival estimates around 60% (26).  Five year relative survival for larynx cancer ranges from 
35.2%-75.9% depending on stage of cancer, while five year relative survival for cancers of the 
oral cavity and pharynx ranges from 37.7%-83.0% (26). 
The incidence and associated mortality of HNC in the US have, overall, shown 
downward trends. However, within certain subpopulations and cancer sites, these trends are not 
consistent. For example, Kingsley et al (2008) found that the incidence of oral cavity cancer in 
Black females from 2000–2004 increased by over 3% (20; 27). Further, Gayar et al. found 
increases in the incidence of oropharyngeal carcinoma among white men from 1973-2009, but a 
decrease in incidence during this same time period among Black men (24). These examples may 
be indicative of the changes in risk factors and behaviors associated with the diagnosis of HNC 
based on sociodemographic differences.  
Risk Factors for Head and Neck Cancer  
HNCs as a group have been associated with a number of risk factors for their 
development. There are two major risk factors associated with HNC diagnosis: substance abuse 
(alcohol and tobacco) and HPV (1). Though these risk factors tend to be discussed most 
frequently in the literature, other risk factors that have also been linked to HNC as described more 
in details in the following sections. 
Tobacco and alcohol use. Substance use, specifically alcohol and tobacco use, is a major 
risk factor for HNC (2). The risk for developing HNC has been shown to be as high as 25 fold 
higher for in those who smoke cigarettes than nonsmokers (28; 29). Further, alcohol consumption 
has been associated with a twofold higher risk of HNC development compared to those who do 
not consume alcohol (2). While both tobacco and alcohol use alone have been shown to be 
independent risk factors, the attributable risk of HNC for the combination of use has been shown 
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to be approximately 75-80% in past literature, indicating there is a synergistic effect (2; 29). As 
risky lifestyle behaviors, such as smoking, have declined in the United States, so have their 
associated cancers, including some forms of HNC. However, new risk factors are being identified 
in relation to HNC incidence.  
Infections. Certain viral infections have been found to be associated with HNC 
development. Epstein Barr Virus (EBV) has been shown to be associated with different cancers in 
humans, including NPC. NPC is more common in areas where the incidence of EBV is high, 
including some African and Asian countries, especially Southern China (30). 
HPV has also been found to be associated with several types of HNC, including oral 
cavity, laryngeal, and hypopharyngeal cancers, but the relationship is inconsistent and not clearly 
related to causation. HPV, particularly subtypes 16 and 18, is most frequently associated with 
oropharyngeal cancers (2). Recent studies on HPV, specifically subtype 16, have suggested that 
this virus may be an independent risk factor for oropharyngeal carcinoma arising in the palatine 
and lingual tonsil tissue (31). Further, HPV-associated HNCs are distinct from non-HPV 
associated HNCs in terms of presentation and prognosis (2). 
The impact of infection on cancer incidence varies by both cancer site, as well as 
geographic location. The global estimated population attributable fraction (PAF) of EBV 
infection for NPC is 85.5%, with a greater number of attributable infections in less developed 
regions. For oropharyngeal cancer, the PAF of HPV infection is 25.6%, but there are a greater 
number of attributable infections in more developed regions (32). These variations are largely due 
to the prevalence of HPV infection in these areas, and may change in response to increasing rates 
of HPV in the future.  
Age, gender, and race. There are differences in HNC incidence across age and gender.  
While there are differences based on specific location and subtype, like many other cancers, 
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HNCs are more likely to be diagnosed in individuals aged 50 and older (33; 34). Based on data 
from the National Cancer Database (NCDB), in the US, nearly 70% of all HNCs occur in 
individuals over the age of 50 (34). However, data from the NCDB also showed that a decline in 
the proportion of squamous cell cancers among older adults, and a greater proportion of HNC 
cases in individuals aged 40-49 years of age (34), which likely is a manifestation of increasing 
HPV-associated cancers of the oropharynx and a decline in tobacco-associated cancers. 
There are also notable gender and racial differences in HNC incidence. In general, the 
male-to-female ratio for HNC is 2:1 to 5:1 (35). However, in recent years, the gap between the 
genders has started to narrow slightly, with declines in HNC incidence being more dramatic in 
males compared to females (36), likely due to declining rates of substance use (37). Further, there 
are racial differences in HNC incidence and mortality in the US, with Blacks bearing a greater 
burden compared to Non-Hispanic Whites (38). 
Other risk factors. Many other factors have been associated with an increased risk of 
HNC. Certain genetic factors have been associated with greater risk of HNC, including 
polymorphisms in genes involved in tobacco and alcohol metabolism (2). Further, studies have 
found that individuals with a family history of HNC are at increased risk for HNC diagnosis (39). 
Certain environmental and occupational exposures such as asbestos and cement, as well as certain 
heavy metals such as nickel and chromium, have been identified as potential risk factors for 
HNCs (40; 41).  
Other factors have also been associated with HNC diagnosis. Lower body mass index has 
also been associated with increased risk of HNC, even after controlling for tobacco and alcohol 
use (42). Similarly, diet has been found to be associated with HNC, with higher consumption of 
red or processed meats associated with a greater risk of HNC, and higher consumption of fruits 
and vegetables associated with a lower risk of HNC (43). Additionally, due to the association 
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between HPV and HNC, sexual history and number of sexual partners has also been found to be 
associated with increased risk for HNC (44). 
Diagnosis of Head and Neck Cancer  
Depending on stage and site, HNC can sometimes be difficult to identify because of 
vague symptoms and location. Symptoms of oral cancers often include non-healing sores in the 
oral cavity, while those of the pharyngeal cancers include symptoms such as sore throat, trouble 
swallowing, or pain in the ear (28; 35). 
The diagnosis of HNC may vary by specific site of cancer within the HNC group. 
However, in general, diagnosis begins with a general physical examination, with a health care 
provider examining all areas of the oral cavity, as well as the nose, ears, scalp, and lymph nodes 
(2; 28). Endoscopy may then be performed for examination of areas such as the nasal cavities, 
base of the tongue, larynx, and pharynx (2; 28). Biopsies may be taken from any abnormal areas 
for further confirmation (2; 28).  
Once cancer is confirmed, there are several tests which can be used to examine the 
extent, or stage, of the disease. Computed tomography (CT) is often performed for this purpose, 
as well as positron emission tomography (PET) (28). Other tests may also be performed, 
including x-ray to examine potential spread to the bone, chest imaging for those at risk for distant 
metastases and molecular and HPV testing of the tumor to guide treatment (2; 28; 45). 
Staging and Treatment of Head and Neck Cancer  
The American Joint Commission on Cancer (AJCC) TNM staging system is often used 
for HNC staging (28). This system utilizes information on tumor size and location, information 
on lymph node spread, and cancer metastasis to stage cancer. Though differences in classification 
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may occur based on specific cancer site, in general, the “T” classifications range from T1 to T4 
depending on size and location of the tumor, with T1 representing the least advanced stage and 
T4 representing the most advanced stage. For this classification, T4 describes advanced stages of 
the disease where the tumor has invaded adjacent structures. The “N” classifications range from 
N0 to N3, with N3 describing metastasis in a lymph node > 6 cm in greatest dimension. Finally, 
the “M” classifications range from M0 to M1, where M1 indicates the presence distant metastasis 
and M0 indicates none (28; 45). Together, these cancer characteristics are used in helping to 
determine the stage of HNC. 
The specific treatment of HNC depends on the site and stage of cancer, side-effects of 
treatments, and patient demographics and preferences (28; 45). Treatment for HNC can involve 
surgery, radiation, chemotherapy, or some combination of these (28; 45). Single-modality therapy 
is the goal when possible. Generally, cancers in the early stages are treated with surgery or 
radiation (28). For more advanced stages, HNC is often treated with surgery, if possible, followed 
by radiation with or without chemotherapy, or with concurrent chemoradiation when tumor 
resections not advisable (28).  
The diagnosis and treatment of HNC is a very complex and multifaceted process. As with 
other cancer, treatment for HNC often involves a multidimensional team approach, utilizing the 
knowledge and skills of different healthcare professionals. Those involved in the treatment of 
HNC may include oncologists, radiologists, and surgical oncologists for the eradication of cancer; 
plastic surgeons, prosthodontists, and physical and speech therapists for physical construction and 
rehabilitation; and psychologists and social workers for the psychological and emotional health of 
patients (45). 
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DEPRESSION IN HEAD AND NECK CANCER 
Cancer and Depression  
Cancer diagnosis and treatment often cause psychological distress for patients. As a 
result, there is a significant body of literature on the relationship between cancer and mental 
health disorders, including anxiety, adjustment disorders, and posttraumatic stress disorder 
(PTSD) (46; 47). However, depression, both diagnosis and symptomology, has received the most 
attention of any psychological illness in previous oncology literature (48). 
Depression is common among cancer patients. In a recent meta-analysis, the prevalence 
of depression in cancer patients ranges from 8% to as high as 27% (49). Further, it has been 
estimated that the occurrence of major depressive episodes among cancer patients is 
approximately two to three times higher than in the general population (50). Overall estimates 
show that the prevalence of major depression in cancer patients range from 3% to as high as 38% 
and that depressive spectrum syndromes among cancer patients may be as high as 52% (51). The 
prevalence of depression varies by several factors including patient characteristics (such as 
gender and age) depression assessment features (such as time of administration and type of 
measurement), as well as clinical factors of cancer diagnosis (49; 52).  
Not surprisingly, clinical features, including stage and specific site of cancer, have also 
been shown to impact estimates of the prevalence of depression in cancer patients. Certain types 
of cancer have been found to have a greater association with depression than others in previous 
literature.  HNCs, along with those of the brain, pancreas, breast, and digestive tract, have been 
associated with higher rates of depression (49; 51). At the time of diagnosis, depression rates in 
HNC have been estimated to be as high as 40%, and depression has been shown to afflict nearly 
30% of HNC patients even three years after diagnosis (51; 53). The diagnosis and treatment of 
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HNC have been associated with high morbidity in patients, including physical disfigurement, loss 
of function, and reduced quality of life (51; 54; 55), all of which may help explain the increased 
risk of depression among HNC patients. Further, lifestyle factors preceding cancer, such as 
excessive tobacco and alcohol use, may be indicative of preexisting depression. 
Depression Preceding Cancer  
The relationship between depression and chronic illnesses, such as diabetes and coronary 
artery disease, is thought to be reciprocal in that one may increase the risk of the other (56). There 
are a number of factors associated with both depression and HNC, including excessive alcohol 
and tobacco use and other poor lifestyle choices (57), which may put this particular cancer patient 
population at higher risk for experiencing depression during cancer diagnosis and recovery. 
However, these factors may also be signs of preexisting depression, indicating that preexisting 
depression may put individuals at risk for developing cancers such as HNC. Because depression 
can affect behavioral risk factors for cancer, there has been speculation as to whether depression 
may influence the incidence of certain cancers (58). 
Depression has been theorized to influence cancer development in one of several ways. 
One theory is that depression may weaken the immune system causing the individual to be at 
greater risk for disease development (59). Another is that chronic stressors associated with 
depression may cause a decrease in deoxyribonucleic acid (DNA) repair enzymes and natural 
killer cells important in apoptosis, therefore allowing malignant cells to grow (59). Others include 
shared genes relating to both diseases, as well as shared behavioral risk factors (59). These 
theories indicate the potential influence of depression on cancer development and suggest 
potential areas of intervention to improve HNC outcomes. 
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While the reciprocal relationship between depression and other chronic diseases has been 
shown (56) there is still significant debate about the reciprocity of depression and cancer, and 
previous research on the topic has led to mixed results. In an examination of patients hospitalized 
for depression in Denmark, the authors found that brain cancers and tobacco-related cancers, such 
as lung cancer, were higher than expected in depressed patients, but that overall cancer incidence 
in depressed patients was not significantly different from national cancer incidence rates (58). 
The authors suggest the results may highlight the negative effect that depression and other mental 
illness may have on health behaviors (58). Further, in a sample of 3,177 individuals in the United 
States followed for 24 years, Gross et al. (2010) found an increased incidence of overall cancer 
and hormonally-mediated cancers, including prostate and breast, among individuals with a history 
of depression (59). However, the authors found no association between depression and other 
cancers including colon, lung, and skin. Because there is still significant debate surrounding the 
influence of depression on cancer development, additional larger, longitudinal studies are needed 
to help understand the relationship between depression and cancer development.  
Depression and Cancer Diagnosis  
Understandably, the diagnosis of cancer can cause significant physical and psychological 
distress. Cancer patients must cope with the physical changes, medical care and financial costs of 
treatment, and time away from family and work. HNC patients may face a number of challenges 
during diagnosis and treatment that may put them at increased risk of depression (54). The 
diagnosis of HNC often carries significant stigma, as these cancers may be seen as self-inflicted 
due to lifestyle choices (60). Further, individuals with depression may present with later stages of 
cancer at the time of diagnosis, resulting in more intensive treatments, higher morbidity, and 
poorer survival outcomes (61). Patients with HNC may be at increased risk of depression because 
many diagnostic and treatment procedures of HNC lead to obvious physical disfigurement, loss of 
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basic functions such as eating and speaking, and other negative side-effects of treatments (53). In 
particular, radiation treatment may result in various side-effects that can impact the psychological 
health of HNC patients.  
Radiation Treatment and Depression  
Radiation therapy, either alone or in combination with surgery, is the typical treatment 
for HNC (62). Though these therapies have been proven to help decrease mortality in HNC 
patients, radiation treatments are frequently associated with several side-effects unique to or more 
severe in this patient population. There are a number of radiation side-effects that can impact the 
daily lives and functioning of HNC patients.  
Oral or dental related diagnoses have been reported in previous studies and may be 
particularly pertinent to the HNC population (63). HNC patients undergoing radiation may have 
oral and dental issues related to cancer itself, but also due to the radiation they receive. Patients 
who receive radiation have been shown to have increased trouble producing saliva and 
swallowing, concerns about social eating due to loss of functioning, dry mouth, increased risk of 
dental caries, and oral infection (63; 64). Further, xerostomia, or dry mouth, has been shown to 
significantly affect functioning and quality of life (65; 66). In fact, in a systematic review by So et 
al. (2012), two of the three most commonly reported side-effects related to quality of life in HNC 
patients were xerostomia and sticky saliva (66). 
Weight loss, loss of appetite, and malnutrition have also been reported side-effects of 
radiation treatment in HNC patients (67; 68). The HNC population has been shown to be at 
increased risk for these side-effects compared to other cancer sites due to both the physical 
obstructions and limitations that may be involved in HNC, as well as potential toxicities from 
treatment (67; 68). Other common side-effects reported in HNC patients include fatigue, pain, 
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and dermatitis (66; 69; 70). These can all negatively affect the psychological health of HNC 
patients and, ultimately, patient outcomes.   
Radiation has also been found to be associated with depression. In a randomized trial of 
the antidepressant escitalopram for the prevention of depression in HNC patients, it was observed 
that the development of depression was more likely to occur in those patients who received 
radiation (71). Furthermore, recent evidence shows suicide risk is also substantially higher in 
HNC patients who receive radiation as part of their treatment (72). 
Depression and Survival Outcomes among Head and Neck Patients 
Depression in HNC and other cancer patients can have a significant and lasting impact on 
these individuals, and this impact can be seen both before and after cancer diagnosis. In general, 
mental illness, such as depression, may lead to less frequent screening for cancer and therefore 
later stage at diagnosis (73; 74). The diagnosis of cancer at later stages can result in more invasive 
treatments and poorer survival probability for patients. In fact, previous research has shown that 
depression in cancer patients results in lower quality of life and may affect survival outcomes (48; 
75). Specific to the HNC population, studies have shown that individuals with HNC have a 
substantially higher risk for completed suicide when compared to other cancers and the general 
population (72; 76; 77). 
Limitations of Previous Research 
Previous literature looking at depression in HNC has estimated the proportion of 
depressed patients in this cancer population to vary widely. This may be due to the differences 
between these earlier studies, as well as the limitations of each. Many previous studies have used 
smaller sample sizes, or single-site hospital-based samples for their research, which may not 
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allow for representative estimates of depression of this population. However, the most significant 
differences among many of these studies were the variation in how depression has been 
measured.  
Depression in previous literature among HNC patients has been assessed by a number of 
different methods. In a systematic review done in 2009, the authors identified over ten different 
inventories, scales, or symptom checklists used to assess depression in HNC patients in over 50 
studies (53). Within each of these studies, even those that used the same inventory utilized 
different cut-off scores for their definition of depression. Further, the type of assessment differed 
amongst many of these studies and included self-report measures, symptom frequency checklists 
administer by a third party, and diagnostic codes found in administrative data. The differences 
among these studies make it difficult, not only to make comparisons among these, but also make 
it difficult to compare the rates of depression between HNC patients and other cancer groups.  
In addition to gaps in the literature regarding depression incidence or prevalence 
estimates in HNC patients, there is also limited information on the prevalence of depression prior 
to cancer diagnosis in this population. Further, there is scarce research examining the influence 
that preexisting depression may have on the stage of cancer at the time of diagnosis in the HNC 
population. A large population-based clinical/administrative database, such as the SEER-
Medicare linked data, offers a unique opportunity to examine depression diagnosis in cancer 
patients in the US, both before and after cancer diagnosis, and help to understand the potential 
reciprocal relationship between depression and HNC throughout the course of cancer.  
SEER-Medicare Linked Database as a Unique Source of Depression Research  
The Surveillance, Epidemiology and End Results (SEER) database is a surveillance 
system designed to track cancer incidence and survival in the US (78). Data collection for this 
15 
 
 
system began in 1973 and it has continued to routinely collect high quality data on cancer 
incidence and mortality over the last four decades. The SEER data cover over 20 geographic 
areas in the United States with 98% completeness, and is considered to be highly valid and 
representative of the US population (79). While SEER data offers much valuable information on 
cancer incidence and outcomes, by itself, it is not able to offer information on risk factors, 
comorbidities, and certain treatments received by the cancer population.  
Starting in 1991, SEER data began being linked to Medicare data in order to fill some of 
the gaps in cancer research. Medicare is a form of public insurance offered to individuals 65 and 
older in the United States, and is the primary insurer for approximately 97% of this population 
(79). Medicare data offer demographic and clinical information on Medicare patients for things 
such as inpatient and outpatient visits, hospice and home health care, and prescription medication 
use (79). The SEER-Medicare data files are linked using a series of algorithms matching 
individuals in the data using identifying information such as name, date of birth, and social 
security number, and approximately 93% of those in the SEER data are successfully linked to 
Medicare files (78). 
SEER-Medicare linked data offer the benefit of having population-based cancer data as 
well as longitudinal information on risk factors and comorbidities found in medical record files. 
Because SEER-Medicare data offer information on medical diagnoses other than cancer, this 
linked dataset has been used in previous studies in order to examine the associations between 
depression and various cancer sites, including breast, prostate, and pancreatic cancers (61; 80; 
81), and therefore may provide an opportunity to compare depression rates in HNC patients to 
those of other cancer sites.  
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Specific Aims  
HNCs are a distressing group of cancers, both physically and emotionally. While there is 
a significant amount of literature examining the relationship between cancer and emotional and 
psychological health, this existing body of literature has not yet fully examined the influence of 
depression on stage at diagnosis, the influence that treatment side-effects may have on depression 
development in these patients, or the role of depression in the survival of HNC. 
The purpose of this dissertation is to examine the psychological aspects of HNC in order 
to fill these gaps in the literature. The first study of this dissertation (Chapter 2) examines the 
existing literature concerning depression in cancer patients and aims to develop a conceptual 
model to better understand the pathways to depression in the HNC population. Utilizing the 
SEER-Medicare linked data, the aims of the second study of this dissertation (Chapter 3) are to: 
(1) estimate the prevalence of depression two years before cancer diagnosis, (2) estimate the 
incidence of emergent depression one year after diagnosis of HNC, and (3) compare stage of 
HNC diagnosis by depression status. The third study (Chapter 4) aims to investigate the 5-year 
survival of HNC patients by depression status, and the final study (Chapter 5) aims to examine 
the association between radiation treatment side-effects and depression outcomes in HNC 
patients. 
 Together, these studies will help to reexamine the existing assumptions of the 
relationship between depression and HNC diagnosis, and provide population-level information on 
the associations between depression and cancer outcomes. The results of these studies may help 
to establish policies for screening for depression in HNC patients at the time of cancer diagnosis, 
but also help in influencing cancer treatment choices based on the risk of depression development 
and standards for continued screening for depression during cancer treatment and recovery.  
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CHAPTER II 
CONCEPTUAL MODEL DEVELOPMENT TO UNDERSTAND THE PATHWAY TO 
DEPRESSION AMONG HEAD AND NECK CANCER PATIENTS 
Abstract 
This paper proposes a conceptual model to understand the development of depression in 
head and neck cancer patients. We conducted literature reviews of existing conceptual models of 
depression among chronic disease patients and risk factors of depression in cancer patients. The 
resulting model shows that both individual and contextual level factors can directly and indirectly 
affect depression outcomes. Additionally, depression diagnosis may also impact treatment 
decisions and lead to poor survival outcomes. The resulting model can help guide future research 
in this and other cancer populations, and be used to develop targeted interventions for depression 
in cancer patients. 
Background 
While cancer patients in general have been shown to be at risk for depression, head and 
neck cancer (HNC) patients experience a number of risk factors for mental illness that are unique 
to this group of cancers (82). Patient lifestyle preceding cancer often includes a history of 
substance use and other high-risk behaviors (57). These behaviors may put individuals at 
increased risk not only for cancer development, but also at increased risk for mental illness both 
before and after cancer diagnosis. Upon cancer diagnosis, HNC patients may be forced to contend 
with feelings of guilt knowing that their past behaviors may have predisposed them to cancer, and 
may experience shame and stigma associated with an HNC diagnosis (83).  During treatment and 
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recovery, HNC patients are often left with functional impairment and physical disfigurement as a 
result of their treatments (57; 84; 85), as well as the struggle associated with withdrawal and 
abstinence from tobacco and alcohol use (86). Though cancer diagnosis has been associated with 
a variety of mental illnesses, including anxiety and post-traumatic stress disorder (46; 47), 
depression may be one of the most prevalent comorbidities in the cancer population (48). 
Previous research has shown that depression may affect anywhere from 9-54% of HNC 
patients during the course of cancer and recovery (53). Preexisting depression has been linked to 
a lower survival, worse nutrition and lower quality of life in HNC patients (87) . In a prospective 
depression prevention trial, emergent depression was strongly associated with radiation therapy 
(88). Further, the rate of suicide in HNC patients has been estimated to exceed most other cancer 
sites, with rates estimated at 53.1 and 46.8 per 100,000 person-years for oral cavity/pharynx and 
larynx cancers compared to 32.4 for all cancers sites combined (72; 77). Suicide appears to be 
especially high in patients that receive radiation therapy (72). Based on existing literature, there is 
an apparent connection between depression and HNC, both before and after cancer diagnosis. 
However, although contributing factors in this population have been identified, the pathway to 
how these factors influence depression development is not well understood and the need for a 
more methodical understanding is acute. 
In health research, conceptual models help to provide a way of unifying and organizing 
ideas to help structure the design and interpretation of studies (89). Additionally, conceptual 
models can aid in research design and offer clinical utility in understanding disease development 
and prognosis. While several conceptual models have been proposed to understand the 
association between depression and cancer, very few have focused specifically on the HNC 
population.  
In their article on depression in HNC patients, Archer et al. developed a conceptual 
model to understand the pathways linking depression and oral cancer, focusing heavily on the 
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biological components of the disease. After a review of the literature, the authors concluded that 
preexisting depression had no effect on cancer incidence. However, the authors developed a 
model to explain the possible effects of stress-hormone activity and increased cytokine levels that 
may lead to increased risk of mortality in cancer patients with depression (82). Emphasizing more 
of psychosocial aspects of disease, Frampton described a conceptual model centering on factors 
relating to psychological distress in relation to the diagnosis of treatment of HNC (90). In this 
model, the author included factors such as body image, social stress, and history of psychiatric 
illness in the development of psychological distress in HNC patients. Additionally, Llewellyn et 
al. used the common sense model framework to describe how HNC patient beliefs about their 
illness influence outcomes such as depression of quality of life (91). While each of these models 
offers insights into the relationships between HNC and depression, they concentrate mostly on 
depression after cancer diagnosis and, therefore, do not fully explain the relationship between 
HNC and depression. 
The purpose of this paper was to develop a conceptual model examining the associations 
between depression and HNC at various time points, both before and after cancer diagnosis. 
Using the current literature of depression development in cancer and other chronic diseases, as 
well as the existing body of knowledge of factors contributing to depression in HNC, we have 
developed a conceptual model to understand the development of depression in HNC patients and 
its influence on cancer outcomes in this population. 
Methods 
A literature search was conducted to identify existing conceptual models of depression 
among chronic disease patients and risk factors of depression in cancer patients. Articles were 
identified by literature database searches of MEDLINE and EMBASE from January 2000-May 
2015. Keywords that were searched included the following: conceptual model, conceptual 
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framework, cancer, depression, and head and neck cancer.  In order to incorporate known factors 
associated with depression in HNC patients, a second literature search was conducted utilizing 
MEDLINE and EMBASE databases from January 2000-May 2015using the keywords depression 
and head and neck cancer. The searches were limited to humans and articles in English.  
Relevant articles were reviewed and variables associated with depression in chronic 
disease patients were extracted from the literature. From these variables, those relevant to the 
HNC population were incorporated into the model. Articles utilizing conceptual models or 
theoretical frameworks were reviewed and relevant aspects were incorporated into the proposed 
conceptual model at various time points over the course of cancer diagnosis and treatment. Using 
previous models as a framework and previous literature identifying factors associated with 
psychological health in HNC patients, we developed a conceptual model of depression in HNC 
focusing on both the effects of depression prior to cancer diagnosis, as well as the development of 
depression following cancer diagnosis. Factors that were related to HNC patients were included 
in the model 
Results 
Our search for conceptual models for depression and cancer or HNC resulted in a total of 
203 unduplicated articles between the searched databases. All abstracts were reviewed for 
relevance, and citations of relevant publications were examined to identify any articles missed in 
the search. This resulted in a total of 47 articles that utilized or developed conceptual or 
theoretical models concerning cancer patients and other chronic diseases with some incorporation 
of the psychological aspects of the disease.  The search for depression and HNC resulted in 426 
unduplicated articles across the databases. Of these, 85 articles were identified which examined 
risk factors for depression development in HNC or identified implications of depression in HNC 
patients. Table1 gives a listing of the various factors influencing depression in HNC patents 
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before and after cancer diagnosis, and Figure 1 shows the proposed conceptual model based on 
our synthesis of the literature. As can be seen from the model, we included factors influencing 
depression prior to cancer diagnosis as well as the influence that cancer diagnosis may have 
depression development. The proposed model incorporates a number of variables found in 
previously proposed models for depression in cancer patients, as well as risk factors that have 
been identified in previous literature. 
Previous models. Our literature search resulted in a number of articles that utilized 
conceptual models or theoretical frameworks which incorporated psychological aspects of cancer 
and other chronic diseases. While several models and frameworks were utilized, the majority of 
these incorporated aspects of transactional theory related to stress, appraisal, and coping. In this, 
psychological symptoms are the response to the relationship between the individual and 
environment, where the person sees the environment as taxing if there is a discrepancy between 
situational demands and personal resources (92; 93). Theories focusing on unpleasant symptoms 
and symptom management were also used as the theoretical framework for several publications 
aimed at understanding performance outcomes in relation to the side-effects of HNC and other 
cancers (94; 95). Additionally, applicable to the HNC population, Cataldo et al. developed a 
conceptual framework surrounding the stigma associated with lung cancer, which incorporates 
both the perception of attitudes toward smoking and smoking-related cancers, as well as personal 
knowledge of the patient (96).   
Factors influencing preexisting depression. A history of depression or depressive 
symptoms has been associated with greater risk of depression at later time points over the course 
of cancer diagnosis and treatment (97-100). In order to focus on the association between HNC 
and depression prior to cancer diagnosis, factors associated with depression in HNC patients were 
applied to the model showing depression development prior to cancer diagnosis. The left side of 
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the model in Figure 1 shows the potential pathways for the individual and environmental 
variables that may be risk factors for the development of depression prior to cancer diagnosis. As 
can be seen in the model, individual differences such as family history of mental illness and 
heredity (82), certain demographic factors such as gender, age, marital and employment status, 
income (53; 101-103) religiosity or spirituality (104), and early childhood experiences (105) can 
all affect the personality, coping style, and worldview of these individuals (106-110). 
Environmental factors, such as family and social environment and patients’ social networks, can 
also affect personality and worldview of an individual (86; 99; 111; 112). Together and 
separately, these can affect depression development prior to cancer diagnosis, as well as exposure 
to potential risk factors, such as smoking and alcohol consumption, which have been associated 
with depression in HNC patients (113). 
Factors such as having a positive social environment and social support, and higher 
education may reduce the likelihood of risky behaviors associated with depression and the 
development of HNC (e.g. smoking and alcohol consumption) (104) or having fewer 
comorbidities and greater overall self-care (53; 114). As can be seen in the model, these not only 
impact the personality and world view of the individual, but may also affect the diagnosis of 
preexisting depression and HNC. For example, improved social support may lead to a lack of 
addiction to tobacco and alcohol that may, in turn, continue to improve this level of social support 
and improve mental and physical health.  
Factors influencing depression after cancer diagnosis. After cancer development and 
diagnosis, individual and environmental factors continue to influence the risk of depression 
development in HNC patients. Factors listed on the left-hand side of the model can continue to 
influence depression status after cancer diagnosis. Additionally, individual factors, such as fear or 
shame concerning the diagnosis (115; 116), as well as clinical factors, such as the specific site 
and stage of cancer, may influence patients’ mental health and coping (86; 117-119). Medical 
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comorbidities and functional status of patients may also influence psychological health (120-124; 
85).  
Likewise, other environmental factors may affect depression status of patients after 
cancer diagnosis. Emotional and social support continue to play a role in depression in HNC 
patients (107; 112; 124-126), as well as experiencing social stigma related to the disease (60). 
Previous literature has also shown that satisfaction with information provided by healthcare 
workers may be associated with better depression outcomes in this patient population (107; 127).  
Because of this, patients’ relationship with healthcare providers was included in the model as part 
of the environmental factors impacting depression outcomes.  
Treatment side-effects appear to play a significant role in depression development in 
HNC patients. Side-effects of treatment such as pain, fatigue, and sleeping difficulties (128- 135) 
speech difficulties (123; 136-138) xerostomia, dysphagia or other swallowing difficulties (134; 
138-142) and trouble eating, loss of appetite, and malnutrition (123; 134; 143-145) have all been 
shown to be associated with the psychological health of HNC patients. Further, surgery and 
disfigurement have also been associated with depression development in HNC patients, in part in 
relation to the loss of function, as well as concerns about body image (146-148). Finally, 
increases in symptoms, as well as receipt of radiation and the associated side-effects of this 
treatment, have been associated with greater risk of depression (62; 149). 
In the proposed conceptual model in Figure 1, individuals may experience side-effects 
associated with treatments, which may vary by cancer site. Patients who are unable physically 
manage these side-effects or emotionally cope with them may be affected by individual and 
environmental factors, such as personal shame and social support, but this relationship can be 
seen as bidirectional, as their inability to cope can also affect these factors.  As an example, a 
patient who experiences a side-effect of trouble with saliva production may feel uncomfortable in 
social eating situations, causing personal shame (139; 140; 144). This may lead to the patient 
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removing themselves from social situations, which limits their social supports and may lead to 
depression.   
Factors influencing HNC outcomes. In terms of depression status and HNC outcomes, 
as is shown in the model, these can be affected by the individual and environmental factors of 
earlier parts of the model (such as cancer stage, medical comorbidities, or economic factors), as 
well as treatments received.  The individual and environmental factors presented earlier in the 
model may influence patients’ ability to cope with the side-effects of treatments that may also be 
associated with overall better self-care. For example, greater education, supportive family 
environments, and greater resources such as income and insurance may be associated with 
improved self-care in these patients and, therefore, better treatment adherence.  Additionally, 
these may be associated with reduced likelihood of returning to prior risky behaviors, such as 
tobacco and alcohol use (150-152), therefore, improving outcomes.  
Depression has been shown to affect treatment decisions of cancer patients (81), which 
can affect mortality rates of these patients. Further, psychological morbidity has also been shown 
to be associated with a greater fear of recurrence in HNC patients (116). Finally, several studies 
have shown that HNC patients who are depressed may have overall lower quality of life (124; 
135; 153; 154), are at greater risk for suicide (72; 76), and have overall worse survival (75; 155).  
Because of the influence that depression may have on quality of life and survival of HNC 
patients, identifying and treating depression in this patient population may be important for 
improving current survival treads of HNCs. 
Discussion 
HNC is especially distressing for patients diagnosed with these cancers. Patients with 
HNC may struggle not only with the physical effects of the disease and its treatments, such as 
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functional impairment and physical disfigurement, but the psychological effects as well.  In 
addition to the influence of any cancer diagnosis, this particular cancer population may be at 
increased risk for psychological illnesses, such as depression, because of the shared risk factors 
for these diseases. Additionally, depression diagnosis prior to cancer may leave these individuals 
at an increased risk for depression recurrence after cancer diagnosis. Further, survival has been 
shown to be lower in patients with preexisting depression (87). Understanding the complex 
relationship between depression and HNC is crucial for future studies in this field. 
As can be seen in the proposed model, there are many individual and environmental 
factors that can influence the diagnosis of depression in the HNC population. Factors such as 
demographics of the patient, social support and network, and clinical variables related to cancer 
may all play a role in the development of depression in HNC patients.  In the model proposed in 
this paper, depression can be seen as both a risk factor for and the result of the diagnosis of HNC, 
and therefore, may be helpful in understanding the full relationship between depression and HNC.   
Previous literature indicates that cancer patients may not be forthcoming about their 
emotional wellbeing during consultations with their physicians (156). Moreover, physicians may 
only briefly discuss psychological or emotional issues with patients, even when patients voice 
concerns (157). The proposed conceptual model may help physicians and other healthcare 
workers to not only identify HNC patients who may be at increased risk for depression 
development, but also to help them understand the effect that depression can have on cancer 
outcomes of their patients.  
Depression has been associated with worse treatment outcomes and poorer quality of life 
in HNC patients. Identifying the pathways by which depression may develop and influence 
patient outcomes is an essential step toward prevention. The model proposed can help guide 
future research in this and other cancer populations, and be used to develop targeted interventions 
for depression in cancer patients.
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Figure 1. Proposed conceptual model of the pathway to depression among HNC patients 
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CHAPTER III 
POPULATION-BASED RETROSPECTIVE STUDY TO INVESTIGATE PREEXISTING 
AND NEW DEPRESSION DIAGNOSIS AMONG HEAD AND NECK CANCER 
PATIENTS 
 
Publication Acknowledgement:  
Rieke K, Boilesen E, Lydiatt W, Schmid KK, Houfek J, Watanabe-Galloway S. Population-based 
retrospective study to investigate preexisting and new depression diagnosis among head and neck 
cancer patients (In Press, Cancer Epidemiology;  DOI:10.1016/j.canep.2016.06.008). 
Abstract 
This study aimed to estimate the pre-cancer prevalence and post-cancer incidence of 
depression in older adult head and neck cancer patients.  Using SEER-Medicare files, cancer was 
identified from SEER data and depression diagnosis was identified using Medicare claims. Of 
3,533 head and neck cancer patients, 10.6% were diagnosed with depression during the two years 
prior to cancer diagnosis, and an additional 8.9% developed depression in the year following 
cancer diagnosis. This study supports the critical need of screening for depression throughout 
cancer diagnosis and treatment, as well as a preventative approach in depression development in 
the older head and neck cancer patient population. 
Introduction 
Head and neck cancers (HNC) have been said to be more emotionally traumatic than 
other types of cancers (57; 158). There are a number of factors shared between depression and 
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HNC, including substance use and other poor lifestyle behaviors, which put this particular cancer 
population at risk for experiencing depression (57). Additionally, HNCs can be especially 
distressing because they can affect patients’ communication and functioning, and may cause 
severe disfigurement (51; 53). Treatment options for HNC, such as radiation therapy, have also 
been associated with increased emotional distress in HNC patients, potentially as a result of the 
side-effects of treatment (62). Recent data demonstrates a higher incidence of depression in 
patients receiving radiation as the primary modality compared with surgery in a randomized trial 
(71). These findings suggest that the long-standing view of disfigurement as the primary cause of 
emergent depression may need to be reconsidered in order to understand how psychiatric illnesses 
impacts patient quality of life and survival.  
The effects of depression in HNC patients can be severe. Studies have shown that HNC 
patients are at higher risk for suicide compared to other cancers and the general population (76), 
and may have poorer quality of life and survival (48; 75). Further, research on other cancer sites 
has shown that poor mental health may lead to less frequent screening and later stage at (73; 74). 
However, even with the shared associations of substance use and high emotional cost, there are 
still knowledge gaps in the literature surrounding depression and HNC.  
Though HNC patients may be at increased risk for depression, currently there is no 
precise estimate of depression in this population. Previous studies, which have been mostly small-
scale, have reported the prevalence to range from 9-54% (53). This wide range may be due to 
differences between these studies such as sociodemographic characteristics, cancer site and 
staging, and the time at which depression was measured. Additionally, many have used self-
reported depression from various inventories with different cut-offs for the definition of 
depression, making it difficult to make cross-study comparisons. There is limited information on 
the effect that preexisting depression may have on cancer stage at the time of HNC diagnosis. 
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Further, lack of longitudinal research has resulted in a limited understanding of depression 
development and outcomes among HNC patients.  
There is a clear need to explore the role of depression in HNC outcomes.  To our 
knowledge, there are no population-based studies that have examined rates of depression in HNC 
patients at multiple time-points or the implications of preexisting depression on cancer stage at 
diagnosis. The specific aims of the study were to: (1) estimate the prevalence of depression two 
years before cancer diagnosis in an older adult head and neck cancer population using 
Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, (2) estimate the 
incidence of depression one year after cancer diagnosis, and (3) compare stage of HNC by 
depression status.   
Materials and Methods 
Study Sample. The sample consisted of individuals diagnosed with HNC from 2004-
2005 who were linked to Medicare data. HNC was identified by International Classification of 
Disease for Oncology, Version 3 (ICD-O3) codes: 000-009 ( lip), 021-023, 030-031, 039-041, 
048-050, 058-062, 068-069 (oral cavity), 019-020,024, 028-029, 051-052, 090-091, 098-103, 
108-109, 140, 142, 148 (oropharynx); 110-113, 118-119 (nasopharynx), 129-132, 138-139 
(hypopharynx), and 320-323, 328-329 ( larynx). Individuals had to have HNC as their only 
cancer diagnosis and be 67 years of age or older at diagnosis in order to ensure a minimum of two 
years of Medicare enrolment prior to cancer diagnosis. Individuals had to be continuously 
enrolled in Medicare Parts A and B for 24 months prior to HNC diagnosis until December of 
2010 or their death, and could not be enrolled in a health maintenance organization (HMO) 
during this same time period to avoid incomplete claims records (74; 81).  
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Depression Identification and Statistical Analysis. From this group, diagnosis of 
depression was identified using ICD-9-CM codes from Medicare claims data. ICD-9-CM codes 
for depression included the following: 300.4 (dysthymic disorder); 296.2-296.24, 296.3-296.34 
(major depression single or recurrent episode); 309.0, 309.1(adjustment disorder with depressive 
symptoms or prolonged depressive reaction); 311 (depressive disorder not otherwise classified); 
296.5-296.54 (bipolar I disorder, most recent episode or current depressed); 298.0 (depressive 
type psychosis); 301.10 (affective personality disorder, unspecified); 301.12 (chronic depressive 
personality disorder); and 301.13 (cyclothymic disorder). To be included in the preexisting 
depression group, subjects had to have at least one inpatient, outpatient, or carrier claim diagnosis 
of depression within the 24 months prior to HNC diagnosis. To be considered part of the post-
HNC depression group, participants could not have been diagnosed with depression before cancer 
diagnosis and had to have a depression diagnosis within the year following cancer diagnosis. 
Individuals diagnosed with cancer at death or autopsy were excluded from all analysis of post-
HNC depression because there was no possibility of depression development.  
All sociodemographic information was taken from SEER data, with education and 
income based on census tract. Receipt of radiation as part of the initial course of treatment was 
included as a dichotomous variable. Medical comorbidity was measured using an adaptation of 
the Charlson Comorbidity Index (CCI) developed for Medicare data, utilizing diagnostic codes 
based on the Deyo method (159-161). Diagnostic codes from inpatient, outpatient, and carrier 
claims during the 12 months prior to cancer diagnosis were used to calculate the index score. 
Stage of cancer diagnosis was taken from the derived SEER Summary Stage.  
Chi-square and t-tests were carried out to examine demographic differences between 
those with and without depression, both before and after cancer diagnosis. Forward selection was 
used to fit the multivariable logistic regression model to examine factors associated with 
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depression at both time points. All data were analyzed using SAS version 9.3.  This study was 
approved by the University of Nebraska Medical Center Institution Review Board. 
Results 
From 2004-2005, 12,175 individuals were diagnosed with HNC. Of these, 2,951 
individuals were excluded because HNC was not their only cancer diagnosis, and 4,315 were 
excluded for being under the age of 67 at the time of HNC diagnosis. Another 151 individuals 
were removed for not being continuously enrolled in Medicare Parts A and B during the study 
period, and 1,225 were removed for being enrolled in an HMO at some point during the study 
period. This left 3,533 individuals in the final sample.   
Prevalence and Incidence of Depression. In total, 375 (10.6%) individuals were 
diagnosed with depression during the two years prior to HNC diagnosis. Table 1 shows the 
characteristics of the sample by preexisting depression status. The groups differed significantly 
by gender, with a higher percentage of females in the depressed group (45.9% vs. 32.5%).  The 
groups also differed by race, with 89.9% of the depressed group being Non-Hispanic White, 
compared to 83.5% of the non-depressed group. Additionally, the groups differed by marital 
status, with 40.5% of depressed subjects being married vs. 52.0% of non-depressed subjects. 
Conversely, 34.1% of depressed patients were widowed compared to 24.5% of the non-depressed 
group. Finally, in the pre-HNC depression group, 20.3% of individuals had a CCI score of one or 
more, compared to 6.3% of the non-depressed group. 
To examine incident depression, we eliminated individuals with pre-existing depression 
and those diagnosed with HNC at death or autopsy, leaving 3,157 individuals. Of these, 
281(8.9%) had a depression diagnosis within the year following HNC diagnosis. Table 2 shows 
the characteristics of subjects by post-HNC depression status. Again, there were significant 
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differences in gender, with 40.6% of the depressed group being female vs. 31.7% of the non-
depressed group. The groups also differed by age, with 35.2% of the depressed group being 70-74 
years old compared to 27.8% of the non-depressed group. There were differences in receipt of 
radiation, with 69.8% of the depressed group receiving radiation compared to 45.7% of the non-
depressed group. Finally, there were differences in stage of cancer at diagnosis, with 19.2% of the 
depressed group diagnosed with distant stage vs. 13.3% of the non-depressed group. 
Multivariable Analysis. Table 3 shows the multivariable logistic regression examining 
factors associated with depression prior to cancer diagnosis. The odds of having depression prior 
to cancer diagnosis differed significantly by gender, with females having 1.59 (95% CI=1.26, 
2.02) times the odds of pre-HNC depression compared to men after adjustment for other variables 
in the model. Race was also associated with pre-HNC depression, with non-White patients having 
lower odds of depression (OR=0.50; 95% CI=0.35, 0.72). Marital status of patients was also 
significant, with those who were divorced/separated (OR=1.52; 95% CI=1.05, 2.21) or widowed 
(OR=1.46; 95% CI= 1.11, 1.92) having greater odds of depression compared to those who were 
married. CCI was associated with pre-HNC depression, with a score of one or more having 4.08 
(95% CI= 3.02, 5.50) times the odds of depression compared to a score of zero. Finally, cancer 
stage was associated with preexisting depression, with distant stage having 1.61 (95%CI=1.17, 
2.22) times the odds of depression compared to local and or regional disease. 
Table 4 shows the multivariable results examining factors associated with developing 
depression within the year following HNC diagnosis.  Age was significantly associated with the 
development of depression after HNC, with those aged 70-74 (OR= 1.53; 95% CI=1.07, 2.18) 
and 80-84 (OR= 1.53; 95%CI=1.01, 2.31) having greater odds of developing depression 
compared to those aged 67-69. In terms of gender, women had 1.57 (95% CI= 1.21, 2.03) times 
the odds of developing depression compared to men. Receiving radiation was associated with 
1.86 (95% CI= 1.40, 2.46) times the odds of developing depression compared to those who did 
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not receive this form of treatment. Finally, in terms of cancer stage, those with distant stage had 
1.72 (95%CI=1.20, 2.47) times the odds of developing depression compared to the non-metastatic 
group. Potential interactions of gender with race and marital status were examined with no 
significant associations found.  
Discussion  
The results of this study show that the prevalence of depression diagnosis during the two 
years prior to HNC diagnosis in older adults was approximately 10.6%. This is slightly higher 
than the prevalence found in SEER-Medicare studies focusing on other cancer sites older adult 
head and neck cancer population. Boyd et al. (2012) (61) found that approximately 7.9% of 
pancreatic adenocarcinoma patients had a depression diagnosis during the 3-27 months preceding 
cancer, while Goodwin et al. (2004) (80) found that approximately 7.5% of breast cancer patients 
had a pre-existing diagnosis of depression during the two years prior to cancer, and Prasad et al. 
(2014) (81) found that approximately 5% of prostate cancer patient had a depression diagnosis 
during this time period. Though the methodologies of these studies were not identical, it appears 
that individuals with HNC may have a modestly higher prevalence of depression before cancer 
diagnosis. Additionally, the present study found that the incidence of depression was 8.9%, 
indicating that almost 9% of individuals without a depression diagnosis prior to HNC were 
diagnosed with depression within one year of cancer diagnosis. This is likely a conservative 
estimate of depression after HNC diagnosis, since this estimate does not include those who were 
part of the preexisting depression group, which may be at risk for continued or recurrent 
depression. Together, the results of this study show the burden of depression in the HNC 
population, both at the time of cancer diagnosis as well as during treatment and recovery.  
This study also showed differences in depression based on gender and race. Gender was 
significantly associated with diagnosis of depression before and after cancer diagnosis, with 
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females having higher odds of depression. This is consistent with previous literature indicating 
that women may be more likely to experience depressive symptoms, or at least are more likely to 
express them to their physician, especially in relation to cancer (74). Similarly, in the 
multivariable analysis, being Non-Hispanic White was shown to be significantly associated with 
depression diagnosis prior to cancer. These results may help in the identification of individuals 
who may be at increased risk for depression.  
The results of this study also indicated that individuals who were divorced/separated or 
widowed at the time of cancer diagnosis had greater odds of experiencing depression prior to 
HNC compared to those who were married. This may be indicative of a lack of social support, 
which has been previously shown to be associated with increased emotional distress in HNC 
patients (162). Additionally, higher medical comorbidities were associated with depression prior 
to cancer diagnoses. While the interaction of marital status and comorbidity score was not shown 
to be significant in the present study, social support may be a common thread among these 
variables in their association with depression.  
 The data showed that individuals receiving radiation as part of their first course of 
treatment had significantly greater odds of developing depression within one year of cancer 
diagnosis.  Previous studies have found that radiation treatment may cause a number of side-
effects including trouble swallowing, dental issues, and trouble hearing (63; 107; 163; 164). It is 
possible that these side-effects may impact patients’ emotional well-being, putting them at risk 
for depression.  Additional factors that may be at play include systemic Il-6 elevation or chronic 
unremitting stress during and after radiation therapy (165). 
Age at the time of cancer diagnosis was also shown to be associated with depression 
development. While the overall association was not shown to be significant, the 70-74 and 80-84 
age groups differed significantly from the 67-69 age group. However, the estimates associated 
with each age group were inconsistent in the direction of their association.  While, in general, 
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younger age has been associated with depression in HNC patients (57) it is possible that the 
restricted age range of this study (age 67+) did not allow linear comparison by the assigned age 
groups.  
Finally, highly advanced stage at diagnosis was shown to be significantly related to 
depression, both before and after cancer diagnosis. The implications of this finding are that 
having preexisting depression may lead to poorer self-care and therefore less frequent physician 
visits, leading to later stage at diagnosis. After cancer diagnosis, stage may be indicative of 
severity of cancer and its side-effects, as well as fear of associated mortality, and therefore lead to 
depression. 
Targeted approaches to diagnose or prevent depression are urgently needed in patients 
undergoing therapy for cancer, and HNC patients are at particular risk. This data supports earlier 
literature of the profile of patients at high risk to develop depression, and thus, trends towards the 
divorced/separated or widowed, white female with comorbidities and later stage of diagnosis who 
will receive radiation therapy as a primary treatment modality. However this is not to say that 
others are not at risk. 
In terms of study limitations, SEER- Medicare files only offer diagnostic codes to 
identify depression. Though we found that nearly 19% of this population was diagnosed with 
depression during the study period, previous studies have found that as high as 54% of the HNC 
population may have some form of depression (53). Utilizing diagnostic codes to identify 
depression may not capture all cases of depression, such as those with subclinical symptoms or 
those who never received a recorded diagnosis, which may underestimate the rates of depression 
in this cancer population. Similarly, SEER-Medicare files only offer diagnostic codes for 
variables concerning substance abuse. While previous literature has shown that diagnostic codes 
for substance abuse disorders are reliable for psychiatric patients (166), patients with mental 
illness may be more likely to receive substance abuse diagnoses than the general population, 
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regardless of substance usage. Because of this, we chose not to examine substance abuse in 
relation to depression outcomes. Additionally, Singer et al. found that HNC patients may 
experience greater emotional distress compared to other cancer sites, but that this relationship 
may be confounded by the level of perceived social support (162).  Because SEER-Medicare data 
does not offer any information on this construct, the effects of social support were not examined 
in this study.  Finally, restricting the age at diagnosis to 67 years and older eliminated more than 
half of all HNC patients, so the study results cannot be generalized to younger HNC patients. 
Conclusions 
This study found that the prevalence of depression diagnosis in older adults prior to 
cancer was 10.6%; modestly higher than in previous studies examining depression in other cancer 
sites using SEER-Medicare data. Additionally, we found that approximately 9% of older adult 
HNC patients had newly diagnosed depression within one year of cancer diagnosis. These results 
support the need for depression screening within this population. It also adds credence to the 
concept of a prevention approach in HNC patients. Given the significant associations of receipt of 
radiation and depression outcomes in this study, there is a need to understand how this treatment 
and its side-effects may affect depression development. Additionally future research of 
depression in HNC patients should focus on the impact that depression has on survival and 
quality of life, as well as identify interventions to prevent post-HNC depression in this patient 
group.  
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Table 1. Demographics by pre-HNC depression diagnosis 
      Yes  (N=375)       No (N=3,158)    
 Variable  Number % Number %  p-value 
Age           0.043 
67-69 61 16.3% 671 21.2% 
  70-74 108 28.8% 899 28.5% 
  75-79 75 20.0% 696 22.0% 
  80-84 70 18.7% 484 15.3% 
  85+ 61 16.3% 408 12.9% 
  Gender          <0.001
Male 203 54.1% 2,133 67.5% 
  Female 172 45.9% 1,025 32.5% 
  Race          0.001
Non-Hispanic white 337 89.9% 2,637 83.5% 
  Other 38 10.1% 521 16.5% 
  % of census tract with 4 year 
college degree           0.185 
0-33% 254 67.7% 2,260 71.6% 
  34+% 93 24.8% 723 22.9% 
  Unknown 28 7.5% 175 5.5% 
  Marital status           <0.001
Married/Living as  152 40.5% 1,642 52.0% 
  Separated/Divorced 43 11.5% 284 9.0% 
  Single 32 8.5% 274 8.7% 
  Widowed 128 34.1% 775 24.5% 
  Unknown 20 5.3% 183 5.8% 
  Median census tract  income          0.934
< $35, 000 or Missing 124 33.1% 1,005 31.8% 
   $35, 000- $44,999 87 23.2% 723 22.9% 
   $45, 000- $59,999 80 21.3% 714 22.6% 
   $60, 000+ 84 22.4% 716 22.7% 
  Cancer site          0.179
Lip 26 6.9% 248 7.9% 
  Oral Cavity 105 28.0% 731 23.1% 
  Oropharynx 101 26.9% 841 26.6% 
  Nasopharynx/Hypopharynx 36 9.6% 283 9.0% 
  Larynx 107 28.5% 1,055 33.4% 
  SEER region          0.363
Pacific/West 156 41.6% 1,201 38.0% 
  Northeast 64 17.1% 637 20.2% 
  Midwest 47 12.5% 435 13.8% 
  South 108 28.8% 885 28.0% 
         CCI       <0.001
0 299 79.7% 2,960 93.7% 
  1+ 76 20.3% 198 6.3% 
  Stage     0.057
Unstaged 51 13.6% 363 11.5%  
In Situ/Localized 149 39.7% 1376 43.6%  
Regional 107 28.5% 983 31.1%  
Distant 68 18.1% 436 13.8%  
CCI= Charlson Comorbidity Index score
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Table 2. Demographics by post-HNC depression diagnosis 
      Yes  (N=281)       No (N=2,876)    
 Variable  Number % Number %  p-value 
Age      0.011 
67-69 52 18.5% 619 21.5%   
70-74 99 35.2% 800 27.8%   
75-79 52 18.5% 644 22.4%   
80-84 52 18.5% 432 15.0%   
85+ 26 9.3% 381 13.2%   
Gender      0.002 
Male 167 59.4% 1,965 68.3%   
Female 114 40.6% 911 31.7%   
Race      0.366 
Non-Hispanic white 240 85.4% 2,396 83.3%   
Other 41 14.6% 480 16.7%   
% of census tract with 4 year college degree      0.370 
0-33% 197 70.1% 2,062 71.7%   
34+% 72 25.6% 651 22.6%   
Unknown 12 4.3% 163 5.7%   
Marital status       0.190 
Married/Living as  131 46.6% 1,510 52.5%   
Separated/Divorced 23 8.2% 261 9.1%   
Single 29 10.3% 245 8.5%   
Widowed 83 29.5% 692 24.1%   
Unknown 15 5.3% 168 5.8%   
Median census tract  income       0.818 
< $35, 000 or Missing 84 29.9% 921 32.0%   
 $35, 000- $44,999 63 22.4% 659 22.9%   
 $45, 000- $59,999 69 24.6% 645 22.4%   
 $60, 000+ 65 23.1% 651 22.6%   
Cancer site      0.859 
Lip 18 6.4% 230 8.0%   
Oral Cavity 66 23.5% 665 23.1%   
Oropharynx 80 28.5% 760 26.4%   
Nasopharynx/Hypopharynx 24 8.5% 259 9.0%   
Larynx 93 33.1% 962 33.4%   
SEER region      0.068 
Pacific/West 98 34.9% 1,103 38.4%   
Northeast 73 26.0% 563 19.6%   
Midwest 40 14.2% 395 13.7%   
South 70 24.9% 815 28.3%   
CCI       0.923 
0 263 93.6% 2,696 93.7%   
1+ 18 6.4% 180 6.3%   
Radiation received      <0.001 
Yes 196 69.8% 1,563 54.3%   
No  85 30.2% 1,313 45.7%   
Stage     0.002 
Unstaged 27 9.6% 335 11.6%  
In Situ/Localized 98 34.9% 1278 44.4%  
Regional 102 36.3% 881 30.6%  
Distant 54 19.2% 382 13.3%  
CCI= Charlson Comorbidity Index score 
 
40 
 
 
 
Table 3. Multivariable logistic regression of depression two years before HNC diagnosis 
  OR   95%  CI   p-value 
Gender      <0.001 
Males  1.00  - -   
       Female  1.59  1.26 2.02   
  
     
Race      <0.001 
Non-Hispanic white 1.00  - -   
Other 0.50  0.35 0.72   
  
     
Marital status      0.052 
Married/Living as  1.00  - -   
Single 1.19  0.78 1.80   
Widowed 1.46  1.11 1.92   
Divorced/Separated 1.52  1.05 2.21   
Unknown 1.11  0.67 1.84   
  
     
CCI       <0.001 
 0  1.00  - -   
 1+ 4.08  3.02 5.50   
  
     
SEER region      0.055 
Pacific/West 1.00  - -   
Midwest 0.74  0.52 1.06   
Northeast 0.66  0.47 0.91   
South 0.86  0.66 1.12   
       
Stage       0.013 
In Situ/Localized 1.00  - -   
Unstaged 1.38  0.96 1.98   
Regional 1.04  0.79 1.36   
Distant 1.61  1.17 2.22   
CCI= Charlson Comorbidity Index score 
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Table 4. Multivariable logistic regression of depression one year after HNC diagnosis 
  OR   95%  CI   p-value 
Age      0.012 
Ages 67-69 1.00  - -   
Ages 70-74 1.53  1.07 2.18   
Ages 75-79 1.00  0.67 1.50   
Ages 80-84 1.53  1.01 2.31   
Ages 85+ 0.88  0.53 1.45   
       
Gender      <0.001 
Males (REF) 1.00  - -   
Female  1.57  1.21 2.03   
       
Race      0.141 
Non-Hispanic white 1.00  - -   
Other 0.77  0.54 1.09   
       
Stage      0.032 
In Situ/Localized 1.00  - -   
      Unstaged 1.12  0.71 1.75   
Regional 1.29  0.95 1.74   
Distant 1.72  1.20 2.47   
       
Radiation received      <0.001 
No  1.00  - -   
Yes 1.86  1.40 2.46   
CCI= Charlson Comorbidity Index score 
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CHAPTER IV 
DEPRESSION AND SURVIVAL IN HEAD AND NECK CANCER PATIENTS 
Abstract 
Objective. Though depression often afflicts head and neck cancer (HNC) patients, few 
studies have examined the association between depression and survival in this particular cancer 
population. The objective of this study is to investigate the five-year survival of HNC patients by 
depression status. 
Materials and Methods. This study used SEER-Medicare data from 2002-2010 and 
identified depression diagnosis two years before and one year after cancer diagnosis. HNC 
patients were identified using ICD-O3 codes and depression was identified using ICD-9-CM 
codes from Medicare claims.  
Results. Of the 3,466 patients included in the study, 642 (18.5%) were diagnosed with 
depression during the study period. Compared to those who received no depression diagnosis, 
those diagnosed with depression prior to cancer or after cancer diagnosis were more likely to die 
of cancer (HR= 1.49; 95% CI=1.27, 1.76 and HR=1.38; 95% CI=1.16, 1.65, respectively). 
Similarly, when looking at death from any cause, those diagnosed with depression prior to cancer 
diagnosis and those who received a diagnosis of depression after cancer were more likely to (die 
from any death compared to those without depression (HR= 1.55; 95% CI=1.36, 1.76 and 
HR=1.40; 95% CI=1.21, 1.62, respectively). 
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Conclusions. The results emphasize the need for early identification and treatment of 
depression in HNC patients, as well as the establishment of policies to routinely screen these 
patients throughout the cancer treatment process. Early detection and treatment of depression in 
these patients may help to improve survival. 
Introduction  
Lower survival and poorer outcomes have been demonstrated in cancer patients with 
depression (81; 167; 168). Previous studies examining depression in cancer populations have 
found higher cancer recurrence and lower quality of life in cancer patients with clinical 
depression or depressive symptomology (167; 169). Depression has also been associated with 
increased mortality in patients with cancer, with mortality rates up to 25% higher in cancer 
patients who experience depression (48; 170). Though previous studies have examined the effect 
that depression may have on cancer mortality rates, there are few large-scale studies that have 
examined the association between depression and survival in patients with head and neck cancers 
(HNC).   
HNC patients face unique psychological challenges compared to many other cancer sites. 
HNCs and their treatments can cause severe physical and functional impairments, which have 
been associated with depression development in HNC patients (51; 53; 106; 146). Further, 
radiation therapy has been shown to be significantly associated with depression (102). Moreover, 
patients with HNC may experience permanent facial disfigurement from treatments (106), and 
unlike other cancer sites, patients may be left with visible scars or deformities that cannot be 
concealed, which may cause issues with personal shame and self-consciousness, and ultimately 
lead to depression (54; 83; 171).  
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Because of the associations between HNC and depression, as well as the psychological 
impact that these cancers and their treatments may have on patients, we previously examined 
depression rates in HNC patients both before and after cancer diagnosis utilizing two linked 
national datasets. The results of this study showed not only that depression diagnosis in HNC 
patients was moderately higher than estimates from other cancer sites, but also that depression 
was associated with advanced stage at diagnosis. However the question still remains as to the 
effect that depression has on the survival of HNC patients. Therefore, the objective of the present 
study is to investigate the five-year survival of HNC patients by depression status. 
Materials and Methods 
We utilized the Surveillance Epidemiology and End Results (SEER)-Medicare linked 
data from 2002-2010. We identified all individuals diagnosed with HNC from 2004-2005 based 
on International Classification of Disease for Oncology, Version 3 (ICD-O3) codes who were 
linked to Medicare data. Individuals had to have HNC as their only cancer diagnosis and be 67 
years of age or older at the time of diagnosis in order to ensure a minimum of two years of 
Medicare enrolment prior to cancer diagnosis. Individuals had to be continuously enrolled in 
Medicare Parts A and B for 24 months prior to their HNC diagnosis until December of 2010 or 
their death, and could not be enrolled in a health maintenance organization (HMO) during this 
same time period due to the possibility of incomplete claims records (74; 81). 
From this group, diagnosis of depression two years prior to cancer diagnosis was 
identified using ICD-9-CM codes from Medicare claims data. To be included in the preexisting 
depression group, subjects had to have at least one claim diagnosis of depression within the 24 
months prior to HNC diagnosis. To be considered part of the post-HNC depression group, 
participants could not have been diagnosed with depression before cancer diagnosis and had to 
have at least one inpatient, outpatient, or carrier claim diagnosis of depression within one year 
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after diagnosis of HNC. Individuals whose reporting source indicated they were diagnosed with 
cancer at the time of death or autopsy were excluded from all analyses for the present study. 
Five-year survival of all patients was examined, with censoring time being December 
2010 (the end of the study period). The survival of patients was identified using the number of 
years and months of survival provided in SEER data. For this variable, survival time was 
calculated using the date of diagnosis and either the date of death, date last known to be alive, or 
December of 2010 for the study data. Survival outcomes of interest included all-cause and 
cancer-specific death based on SEER data reporting. For all-cause mortality, vital status at the 
end of the study period (December 2010) was used. For cancer specific survival, deaths attributed 
to HNC were treated as events and deaths from other causes were treated as censored observation 
(78). 
Statistical analysis. Kaplan-Meier curves were used to examine basic survival estimates 
by depression status of patients. Cox regression models were used to control for potential 
confounding variables. Covariates included in the models were determined using forward 
selection and clinical importance. Candidate covariates included sociodemographic information 
taken from SEER data, with education and income based on census tract. Because survival 
outcomes may differ by treatment received, radiation as part of the initial course of treatment 
(dichotomous variable) was included as a potential covariate. Additionally, because survival may 
differ by time of onset of depression, depression based on time of diagnosis was examined as a 
potential covariate in the model. Medical comorbidity was measured using an adaptation of the 
Charlson Comorbidity Index (CCI) developed for Medicare data (159-161). All analyses were 
performed using SAS 9.4, with the default method used to handle ties within the data (Breslow 
method). For the multivariable models, time-dependent variables were entered into the models to 
test the proportional hazards assumption of each variable. Forward selection was used to fit the 
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models, with significant time-dependent variables left in the model as the interaction of each of 
these time-dependent variables with survival time. 
Results 
Bivariate analysis. Based on the inclusion and exclusion criteria listed above, there were 
3,533 individuals eligible for inclusion in the analyses. From these, an additional 67 individuals 
were excluded for being diagnosed with cancer at the time of death or autopsy, leaving a total of 
3,466 individuals in the study sample (Appendix A).  Table 1 shows the demographic and clinical 
characteristics of the study sample by depression status over the course of cancer. Of the study 
sample, 361 individuals (10.4%) had a diagnosis of depression prior to HNC diagnosis, an 
additional 281 individuals (8.1%) developed depression after cancer diagnosis, and 2,824 
individuals (81.5%) were not diagnosed with depression at any point during the study period. As 
can be seen from Table 1, there were significant differences between the groups in terms of 
survival for both cancer–specific and all-cause mortality. For cancer-specific deaths, there were 
over 35% more deaths from cancer in those who were diagnosed with depression prior to cancer 
compared to those who were never diagnosed with depression (48.8% vs. 36.0%, respectively). 
Similarly, there were over 41% more deaths from cancer in those who were diagnosed with 
depression after their cancer diagnosis compared to those where never diagnosed with depression 
(50.9% vs. 36.0%, respectively). Other significant differences between groups included age, 
gender, ethnicity, marital status, stage, medical comorbidity, and receipt of radiation. When 
looking at all-cause mortality, there were over 35% more deaths in the group diagnosed with 
depression prior to cancer diagnosis compared to those who were never diagnosed with 
depression (77.6% vs. 57.4%, respectively). Similarly, when looking at those who developed 
depression after cancer diagnosis compared to those who were never diagnosed with depression, 
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there were nearly 30% more deaths in the group that developed depression after cancer (74.4% 
compared to 57.4%, respectively).  
The Kaplan-Meier survival curves for cancer-specific death by depression status showed 
those without a diagnosis of depression during the specific time period had better survival 
compared to those who received a depression diagnosis, either before or after cancer (Log Rank 
chi square =63.03, p=<0.0001). Those who received a diagnosis of depression prior to cancer had 
a median survival time of 37 months, compared to 29 months for those who received a diagnosis 
of depression after cancer diagnosis. The median survival time could not be computed for those 
who received no diagnosis of depression as median survival exceeded the 60 month follow-up 
period. 
Similarly, for all-cause mortality, individuals without a depression diagnosis had better 
survival outcomes compared to those who received a depression diagnosis, either before or after 
cancer diagnosis (Log Rank chi square = 99.56, p=<0.0001). Those who received a diagnosis of 
depression prior to cancer had a median survival time of 17 months, compared to 18 months for 
those who received a diagnosis of depression after cancer diagnosis, and 46 months for those who 
received no diagnosis of depression.   
Multivariable Analysis. Table 2 shows the multivariable analysis results for the outcome 
of cancer-specific death. As can be seen from the table, depression diagnosis was significantly 
associated with cancer death in the multivariable model after controlling for all other covariates. 
Compared to those who received no depression diagnosis, those who were diagnosed with 
depression prior to cancer diagnosis had nearly 1.5 times the hazard of cancer death, while those 
who were diagnosed with depression after cancer diagnosis had nearly 1.4 times the hazard of 
cancer death. Other significant variables associated with cancer death included age, marital status, 
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income, specific cancer site, stage at diagnosis, medical comorbidity, receipt of radiation and the 
interaction of receipt of radiation over time.  
The multivariable results for all-cause mortality are show in Table 3. Again, depression 
was found to be significantly associated with the outcome after controlling for demographic and 
clinical variables. Those who were diagnosed with depression prior to cancer diagnosis had 1.55 
times the hazard of any death compared to those who received no depression diagnosis. Similarly, 
those who received a diagnosis of depression after had 1.40 times the hazard of any death. Other 
variables that were found to be significantly associated with all-cause mortality included age, 
marital status, gender, race, income, specific cancer site, stage at diagnosis, medical comorbidity, 
receipt of radiation, and the interaction of time with age, marital status, race, and receipt of 
radiation.  
Discussion 
This study showed that HNC patients with a diagnosis of depression had significantly 
greater risk for death from cancer and death from any cause. Even after controlling for potential 
confounding variables, including stage of cancer at the time of diagnosis, individuals with a 
diagnosis of depression had 38% and 49% greater hazard of cancer-specific mortality and 40% 
and 55% greater hazard of all-cause mortality compared to those patients who never received a 
depression diagnosis.  
The results of our study support those of several previous studies which have examined 
the association of depression on the survival of various types of cancer. Patients with cancers 
such as those of the breast (80; 168; 172), prostate (81), and lung (173) who also struggle with 
depression or depressive symptoms have been shown to have decreased survival compared to 
their non-depressed counterparts. Several previous studies of smaller scale have also examined 
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the association of depression on survival of individuals with cancers of the head and neck. In a 
prospective study of 241 patients, Kim et al. found that HNC patients with pre-treatment 
depression had decreased 3-year survival compared to their non-depressed counterparts (87).  In a 
clinical trial of prophylactic depression treatment of HNC patients, Lazure et al. found that 
patients with depression had significantly greater mortality and disease recurrence compared to 
those who were not depressed (75). Similarly, Shinn et al. found that, of 130 patients with 
oropharynx cancer, self-reported depression was associated with a 3.6 greater hazard of death and 
3.8 greater hazard of disease recurrence (167). Further, Kam et al. found that individuals with 
HNC have 3 times greater incidence of suicide compared the general population in the United 
States (72). They also found an association with radiation and depression which is again 
confirmed in this study. Previous work by our group has also shown a higher risk of emergent 
depression in patients that undergo radiation as part of their primary treatment for HNC (71). 
Together with the present study, these studies underline the importance of patient psychological 
health during the diagnostic and treatment process of HNC, as well as the need for the recognition 
of past and current depressive symptoms by clinicians especially in those undergoing radiation as 
part of their treatment.  
The present study adds to the existing literature of the effects of depression on survival of 
HNC in several ways. By utilizing a large, population-based sample, this study provides 
information on the relationship between depression and survival which may be more 
representative of the elderly HNC population than previous smaller-scale studies. Further, by 
examining the diagnoses of depression both before and after cancer diagnosis, the results offer a 
unique look at the influence that pre-existing depression may have on cancer outcomes, in 
addition to incident depression after cancer diagnosis. Based on our findings, future studies 
examining outcomes of HNC and other cancer patients should consider both current and 
historical psychological health of patients.  
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In terms of study limitations, we identified depression based on ICD-9-CM codes, 
thereby limiting our findings to only those individuals with diagnosed depression. Because of 
this, we are not able to capture the influence that sub-clinical or underdiagnosed depression may 
have on survival outcomes of this population. Additionally, our study did not include information 
on depression treatments received, which may have additional influence on survival. Further, 
Medicare only includes data in individual 65 and older, and the present study included only 
individuals 67 years of age and older in order to be able to examine depression diagnosis prior to 
cancer. The age limitation of both the data and our selection criteria do not allow for the 
examination of the effect of depression on younger patients. Another limitation of the present 
study is the lack of information on human papillomavirus (HPV) status of the study subjects. 
Previous research on oropharyngeal cancer has shown that HPV-positive patients may have better 
survival than those without the virus (174). Unfortunately, because there is no information on 
HPV status within SEER-Medicare files, we were unable to examine or control for this 
relationship in our study. However, this may only affect survival of patients with specific forms 
of HNC, and the current study can still be used to estimate the effect of depression on survival of 
HNCs as a group. Strengths of the present study include a large sample size as well as 
diagnostically confirmed cancer and depression in the selected sample.  
Conclusion 
In our study, depression diagnosis was associated with decreased survival in HNC 
patients. These results emphasize the need for strategies designed to prevent depression, early 
identification and treatment of depression in HNC patients, as well as the establishment of 
policies to routinely screen these patients throughout the cancer treatment process. Identifying 
and treating depression in these patients may not only help to improve quality of life during 
cancer treatment and recovery, but may also help to improve survival in these patients. 
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Table 1. Profile of the study sample by depression status 
  
Pre-Cancer 
Depression (N=361) 
Post-Cancer 
Depression  
(N=281) 
No Depression 
(N=2,824) p-value 
 Variable  N % N % N %   
Age             0.0061 
67-69 60 16.6% 52 18.5% 615 21.8%   
70-74 106 29.4% 99 35.2% 788 27.9%   
75-79 73 20.2% 52 18.5% 635 22.5%   
80-84 68 18.8% 52 18.5% 418 14.8%   
85+ 54 15.0% 26 9.3% 368 13.0%   
Gender             <0.0001 
Male 196 54.3% 167 59.4% 1931 68.4%   
Female 165 45.7% 114 40.6% 893 31.6%   
Ethnicity              0.0059 
Non-Hispanic white 324 89.8% 240 85.4% 2353 83.3%   
Other  37 10.2% 41 14.6% 471 16.7%   
% With 4 year college degree             0.3212 
0-33% 245 67.9% 197 70.1% 2025 71.7%   
34+% 90 24.9% 72 25.6% 644 22.8%   
Missing 26 7.2% 12 4.3% 155 5.5%   
Marital status              0.0002 
Married/Living as Married 148 41.0% 131 46.6% 1499 53.1%   
Separated/Divorced 39 10.8% 23 8.2% 249 8.8%   
Single 31 8.6% 29 10.3% 239 8.5%   
Widowed 124 34.3% 83 29.5% 671 23.8%   
Unknown 19 5.3% 15 5.3% 166 5.9%   
Median Income Census Tract               0.9547 
< $35, 000 or Missing 118 32.7% 84 29.9% 897 31.8%   
 $35, 000- $44,999 86 23.8% 63 22.4% 649 23.0%   
 $45, 000- $59,999 75 20.8% 69 24.6% 633 22.4%   
 $60, 000+ 82 22.7% 65 23.1% 645 22.8%   
Cancer Site             0.3433 
Lip 26 7.2% 18 6.4% 228 8.1%   
Oral Cavity 103 28.5% 66 23.5% 654 23.2%   
Oropharynx 96 26.6% 80 28.5% 736 26.1%   
Nasopharynx/Hypopharynx 35 9.7% 24 8.5% 255 9.0%   
Larynx 101 28.0% 93 33.1% 951 33.7%   
SEER Region             0.0572 
Pacific/West 155 42.9% 98 34.9% 1085 38.4%   
Northeast 57 15.8% 73 26.0% 558 19.8%   
Midwest 47 13.0% 40 14.2% 391 13.8%   
South 102 28.3% 70 24.9% 790 28.0%   
Stage             0.0021 
Unstaged 37 10.2% 27 9.6% 285 10.1%   
InSitu/Localized 149 41.3% 98 34.9% 1278 45.3%   
Regional  107 29.6% 102 36.3% 881 31.2%   
Distant 68 18.8% 54 19.2% 380 13.5%   
Charlson Comorbidity              <0.0001 
0 290 80.3% 263 93.6% 2650 93.8%   
1+ 71 19.7% 18 6.4% 174 6.2%   
Radiation Received             <0.0001 
No  186 51.5% 85 30.2% 1261 44.7%   
Yes 175 48.5% 196 69.8% 1563 55.3%   
        
Any Death             <0.0001 
No  81 22.4% 72 25.6% 1204 42.6%   
Yes 280 77.6% 209 74.4% 1620 57.4%   
Cancer Death             <0.0001 
No  185 51.2% 138 49.1% 1808 64.0%   
Yes 176 48.8% 143 50.9% 1016 36.0%   
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Table 2. Multivariable results for cancer-specific mortality  
 Variable  
HR   95% CI   p-value 
Type 3  
p-value 
Depression Status             <0.001 
No Depression Diagnosis REF 
 
- - 
  
  
Pre-HNC Depression 1.49 
 
1.27 1.76 
 
<0.001   
Post-HNC Depression 1.38 
 
1.16 1.65 
 
<0.001   
Age           <0.001 
67-69 REF 
 
- - 
  
  
70-74 1.15 
 
0.98 1.36 
 
0.098   
75-79 1.55 
 
1.30 1.84 
 
<0.001   
80-84 1.83 
 
1.52 2.20 
 
<0.001   
85+ 2.32 
 
1.90 2.82 
 
<0.001   
Marital Status           <0.001 
Married/Living as Married REF 
 
- - 
  
  
Single  1.30 
 
1.07 1.57 
 
0.008   
Widowed 1.41 
 
1.24 1.06 
 
<0.001   
 Divorced/ Separated  1.44 
 
1.19 1.74 
 
<0.001   
Unknown 1.06 
 
0.80 1.39 
 
0.702   
Median Income Census Tract             <0.001 
< $35, 000 or Missing REF 
 
- - 
  
  
 $35, 000- $44,999 0.77 
 
0.66 0.89 
 
<0.001   
 $45, 000- $59,999 0.72 
 
0.61 0.84 
 
<0.001   
 $60, 000+ 0.71 
 
0.61 0.82 
 
<0.001   
Cancer Site           <0.001 
Lip REF 
 
- - 
  
  
Larynx 3.54 
 
2.38 5.24 
 
<0.001   
Nasopharynx/Hypopharynx 5.52 
 
3.64 8.35 
 
<0.001   
Oral Cavity  3.47 
 
2.34 5.15 
 
<0.001   
Oropharynx 3.71 
 
2.49 5.52 
 
<0.001   
Stage           <0.001 
In Situ/Localized REF 
 
- - 
  
  
Regional  3.30 
 
2.83 3.86 
 
<0.001   
Distant 4.93 4.17 5.83 <0.001   
Unstaged 2.68 
 
2.20 3.28 
 
<0.001   
Charlson Comorbidity            <0.001 
0 REF 
 
- - 
  
  
1+ 1.47 
 
1.21 1.80 
 
<0.001   
Radiation Received           <0.001 
No REF 
 
- - 
  
  
Yes 0.48 
 
0.41 0.57 
 
<0.001   
Radiation*TIME 1.03  1.02 1.04  <0.001 <0.001 
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Table 3. Multivariable results for all-cause mortality 
 Variable  
HR   95% CI   p-value 
Type 3  
p-value 
Depression Status              <0.001 
No Depression Diagnosis REF 
 
- - 
  
  
Pre-HNC Depression 1.55 
 
1.36 1.76 
 
 <0.001   
Post-HNC Depression 1.40 
 
1.21 1.62 
 
 <0.001   
Age            <0.001 
67-69 REF 
 
- - 
  
  
70-74 1.15 
 
1.00 1.33 
 
0.052   
75-79 1.47 
 
1.26 1.73 
 
 <0.001   
80-84 1.67 
 
1.39 2.02 
 
 <0.001   
85+ 2.40 
 
1.96 2.95 
 
 <0.001   
Age*TIME 1.00  1.00 1.01   <0.001  <0.001 
  
      
  
Marital Status        <0.001 
Married/Living as Married REF 
 
- - 
  
  
Single  1.38 
 
1.16 1.63 
 
 <0.001   
Widowed 1.62 
 
1.40 1.88 
 
 <0.001   
 Divorced/ Separated  1.52 
 
1.29 1.78 
 
 <0.001   
Unknown 1.31 
 
1.03 1.67 
 
0.028   
Marital*TIME 1.00  1.00 1.00  0.015 0.015 
  
      
  
Gender        <0.001 
Male REF 
 
- - 
  
  
Female 0.84 
 
0.76 0.93 
 
 <0.001   
Race           0.003 
Non-Hispanic white REF 
 
- - 
  
  
Other  1.28 
 
1.09 1.51 
 
0.003
 Race*TIME 0.99  0.99 1.00   <0.001  <0.001
  
      
  
Median Income Census Tract          <0.001 
< $35, 000 or Missing REF 
 
- - 
  
  
 $35, 000- $44,999 0.82 
 
0.73 0.92 
 
 <0.001   
 $45, 000- $59,999 0.75 
 
0.66 0.84 
 
 <0.001   
 $60, 000+ 0.73 
 
0.64 0.82 
 
 <0.001   
Cancer Site            <0.001 
Lip REF 
 
- - 
  
  
Larynx 1.66 
 
1.35 2.05 
 
 <0.001   
Nasopharynx/Hypopharynx 2.46 
 
1.93 3.13 
 
 <0.001   
Oral Cavity  1.61 
 
1.30 1.99 
 
 <0.001   
Oropharynx 1.74 
 
1.40 2.16 
 
 <0.001   
Stage            <0.001 
In Situ/Localized REF 
 
- - 
  
  
Regional  2.34 
 
2.08 2.63 
 
 <0.001   
Distant 3.27 2.86 3.73  <0.001  
Unstaged 2.08 
 
1.79 2.43 
 
 <0.001   
Charlson Comorbidity             <0.001 
0 REF 
 
- - 
  
  
1+ 1.86 
 
1.61 2.15 
 
 <0.001   
Radiation Received            <0.001 
No REF 
 
- - 
  
  
Yes 1.64 
 
1.44 1.88 
 
 <0.001   
Radiation*TIME 1.01  1.01 1.02   <0.001  <0.001 
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CHAPTER V 
RADIATION SIDE-EFFECTS AND DEPRESSION IN HEAD AND NECK CANCER 
PATIENTS 
Abstract 
Background. The influence of radiation side-effects on psychological distress of head 
and neck cancer (HNC) patients is not well understood. The objective of this study was to 
examine the association between radiation treatment side-effects and depression outcomes in 
HNC patients.  
Methods. SEER-Medicare data was examined for 1,759 HNC patients who received 
radiation as part of their initial course of treatment. Radiation side-effects in Medicare data were 
identified and examined in their association with one year post-cancer depression diagnosis.  
Results. Nearly 85% of those in the depressed group were diagnosed with at least one 
radiation side-effect, compared to 59% of the non-depressed group. A diagnosis of at least one 
radiation side-effect was associated with 3.70 (95% CI= 2.47, 5.55) times the odds of being 
diagnosed with depression.  
Conclusions. It appears that potential side-effects of radiation are associated with the 
emotional well-being of HNC patients during the first year following cancer diagnosis.  
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Introduction 
Radiation therapy is a well-established treatment for head and neck cancers (HNC), with 
half or more of all HNC patients receiving some form of radiation as part of their cancer 
treatment (34; 175). Unfortunately, this treatment has also been associated with a number of side-
effects and toxicities which can be detrimental to HNC patients (55; 62; 176). Common side-
effects of radiation treatment in HNC patients include xerostomia (dry mouth) and other salivary 
problems, oral health issues, malnutrition, and extreme fatigue (63-68). These side-effects can not 
only cause physical impairment in HNC patients, they may also affect the emotional well-being 
of these individuals (62; 176). 
HNC patients in particular may be at risk for depression development due to the physical 
disfigurement and functional impairment that accompany the treatment of these cancers (53; 54). 
Previous literature has shown that individuals who receive radiation treatment have poorer quality 
of life and may have increased mental health issues or mental distress (67; 71). Further, patients 
who received radiation therapy have been shown to have an increased risk of depression 
development as treatment persists (62). While this treatment modality may be beneficial for 
survival, there is a dearth of research examining the influence that radiation side-effects may have 
on the psychological health of this group of patients already at risk for depression.  
Though previous studies have suggested that radiation side-effects may influence 
psychological health (62; 102; 134; 176), few studies that have specifically examined the 
influence of treatment side-effects on depression development in HNC patients, even though the 
risk in this population may particularly high. Because of the frequency of radiation treatment and 
increased risk for psychological illness or distress in this population, and the treatment options 
available for depression, there is a clear need to explore the associations between the side-effect 
of this treatment and depression diagnosis in HNC patients. The objective of the present study 
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was to examine the association between radiation treatment side-effects and depression outcomes 
in HNC patients.  
Methods 
The methods for sample selection have been previously reported (177). Briefly, utilizing 
Surveillance Epidemiology and End Results (SEER)-Medicare linked data from 2002-2010, we 
identified all individuals diagnosed with HNC from 2004-2005. From this group, diagnosis of 
depression was identified using ICD-9-CM codes from Medicare inpatient, outpatient, or carrier 
claim claims data. Individuals whose reporting source indicated they were first diagnosed with 
cancer at the time of death or autopsy were excluded from all analysis. For the present study, we 
excluded individuals who had a diagnosis of depression during the two years prior to their cancer 
diagnosis in order to be able to capture incident depression cases. The study sample was also 
limited to those individuals who received radiation as part of their initial course of treatment, 
either alone or in addition to other treatments. 
ICD-9-CM codes for potential side-effects of radiation treatment were identified from 
previous literature and clinical judgment. Side-effect diagnostic codes included: Xerostomia 
(527.7); Dysphagia (787.2, 787.21-787.24, 787.29); Aspiration (507.0, 508.9); Malnutrition (260, 
261, 262, 263, 263.1, 263.8-263.9, 799.4); Fatigue or Malaise (780.7, 780.79); Radiation sickness 
(366.46, 692.82, 990, 909.2); Speech disturbances (784.59, V40.1, V57.3); and Dental caries 
(521, 521.01-521.04, 521.06-521.09; 525.13; 526.89). Patients had to have at least one inpatient, 
outpatient, or carrier claim diagnosis of a given side-effect within one year of cancer diagnosis to 
be included within a given side-effect group.  
Bivariate analyses were carried out to examine basic differences in side-effects between 
those with and without a depression diagnosis. Multivariable logistic regression was used to 
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examine the association between side-effects and depression outcomes while controlling for 
potential confounding factors. All two-way interactions were investigated between the following 
variables: race, income, age, sex, cancer stage and site. Forward selection was used to fit the 
multivariable logistic regression model with the p-value<0.15 for entry and data were analyzed 
using SAS version 9.4. 
Results 
Bivariate Analysis. The final sample included 1,759 patients who were diagnosed with 
HNC between 2004-2005 and met all inclusion criteria for the study. Table 1 shows the 
demographic and clinical characteristics of the study sample by depression status.  The only 
significant differences in group characteristics were gender and marital status. A greater 
proportion of those in the non-depressed group were male (72.9% versus 58.7%), and a greater 
proportion of those in the non-depressed group were married or living as married at the time of 
diagnoses when compared to the depressed group (57.6% versus 49.5%, respectively). 
Table 2 shows the radiation side-effects in the study sample by depression status. Overall, 
there were significant differences in diagnosed side-effects by depression status for all side-
effects examined (dysphagia, aspiration, malnutrition, and fatigue or malaise), other than 
xerostomia. Other than the xerostomia, over three quarters of the depressed group had a diagnosis 
of each side-effect, compared to less than half in of the non-depressed group. Though the 
difference was not statistically significant, a greater proportion of the depressed group received a 
diagnosis of xerostomia compared to the non-depressed group (10.2% versus 6.8%, respectively). 
When looking at all side-effects combined, nearly 85% of the depressed group had at least one 
side-effect diagnosis in the year following cancer diagnosis, compared to only 59% in the non-
depressed group.  
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Multivariable Analysis. Table 3 shows the multivariable results of the factors associated 
with depression diagnosis in HNC patients. As in the bivariate analysis, females had greater odds 
of receiving a diagnosis of depression following HNC when compared to males (OR= 1.78; 95% 
CI= 1.30, 2.44). As can be seen from the table, gender and side-effect diagnosis were 
significantly associated with depression diagnosis.  Having diagnosis of at least one radiation 
side-effect was associated with 3.70 (95% CI= 2.47, 5.55) times the odds of being diagnosed with 
depression compared to those with no radiation side-effect diagnoses.  
Discussion 
In this study, over half of the patient sample received a diagnosis of dysphagia, 
aspiration, malnutrition, or fatigue or malaise during the year following cancer diagnosis. Further, 
nearly 62% of the HNC patient sample had at least one potential radiation side-effect diagnosis 
within the first year of cancer diagnosis. Specific to the influence of side-effects on psychological 
health of patients, nearly 85% of those with a depression diagnosis were also diagnosed with at 
least one radiation side-effect, compared to only 59% of the non-depressed population. Even after 
controlling for age, gender and ethnicity, HNC patients who had received a diagnosis of at least 
one of the proposed radiation side-effects had nearly four times the odds of depression compared 
to those with no side-effect diagnoses. Based on the results of this study, it appears that potential 
side-effects of radiation are associated with the emotional well-being of HNC patients during the 
first year following cancer diagnosis. 
The results of the present study add to and are supported by the existing literature 
examining the association of radiation and depression in the HNC population. Chen at al. (2010) 
found that symptom severity related to oral cancer was significantly associated with both 
depression and radiation dose in a sample of 76 oral cavity cancer patients receiving radiation 
(134). Additionally, Nguyen et al. (2010) found that severity of dysphagia was associated with 
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risk of depression in HNC patients (178). Previous work by Kelly at al. (2007), Rose at al. (2001), 
and Chen et al. (2009) found that patients receiving radiation treatment had increased level of 
depression as their radiation treatment progressed (62; 102; 176). Comparing radiation treatment 
with other cancer treatments, in a clinical trial of prophylactic antidepressant use in HNC patients, 
Lydiatt et al. (2013) found that individuals who received radiation as part of their initial course of 
treatment had greater mean depression rates compared to those who only received surgery (71). 
Additionally, Kam et al. (2015) found that HNC patients treated with radiation only or radiation 
with surgery had greater incidence of suicide compared to those treated with only surgery (72).  
There are several limitations that should be taken into account when interpreting the 
results of this study. First, we identified depression in this patient population by diagnostic codes 
from Medicare data. Because of this, HNC patients with subclinical or undiagnosed depression 
were not included in the depression group in this study. Further, we eliminated those with pre-
existing depression from inclusion in the study, a group which may be more likely to develop 
depression after cancer diagnosis. In spite of this, the significant results of this study are still 
relevant, since any subsequent misclassification would result in an underestimate of the influence 
that radiation side-effects have on depression diagnosis in the HNC population. Another 
limitation of this study is the lack of ability to identify a temporal relationship between depression 
development and radiation side-effects. Receipt of a diagnosis of both depression or side-effects 
of radiation would require a scheduled appoint with a healthcare provider and diagnostic date 
would, therefore, depend on appointment availability. Because of this, the analysis of this study 
only examined the association between side-effect diagnosis and depression diagnosis with the 
year following HNC diagnosis, without concern for which was diagnosed first. Further, this study 
focused on patients who received radiation with or without other treatments.  It is possible that 
additional treatments, such as surgery or chemotherapy, may be indicative of severity of cancer or 
of other side-effects, such as physical disfigurement, and therefore be associated with depression 
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development. However, given the nature of the data, additional treatments would only be proxies 
for factors, and therefore were not included in the analyses. Finally, diagnostic codes for the side-
effects of radiation were taken from previous literature and identified through medical records. It 
is possible that these side-effect diagnoses were unrelated to radiation treatments received by 
patients. However, the side-effects diagnostic codes used in this study were limited to those 
reported more commonly in the literature or that are specific to radiation treatments, giving 
credence to the results.  
The study has several implications on both clinical practice and future research. First, for 
patients who will be undergoing radiation treatment, prevention measures should be taken prior to 
treatment initiation in order to help reduce side-effect symptomology. As outlined in a review by 
Andrews and Griffiths (2001), there are a number of prevention and management efforts that can 
be made in order to reduce dental complications associated with radiation therapy including pre-
treatment assessments and potential extractions. Use of agents such as oral lubricants or 
fluoridation methods in irradiated patients may help reduce oral and dental complications (179). 
Further, monitoring of side-effects and treatment of side-effects in patients may be necessary in 
order to improve psychological health and quality of the in these patients. Follow up support 
during treatment, such as nutritional counselling, may be beneficial in helping to each side-effects 
of radiation. In practice, healthcare providers should monitor and screen patients undergoing 
radiation treatment for depression on a regular basis, especially those who develop treatment side-
effects. In terms of implications on research, future studies examining psychological well-being 
in the HNC population should include information about treatments received and the side-effects 
associated with these treatments. Additionally, future prospective studies should also include 
information on physical disfigurement and functional impairment that may be caused by 
additional treatment received, such as surgery. Finally, the present study was unable to show 
temporality in the relationship between side-effect diagnoses and depression, and therefore unable 
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to determine a causal relationship. Future research should try to identify whether side-effects 
precede depression, or whether depression precedes side-effects in order to potentially improve 
depression screening or side-effect outcomes in the HNC population.   
Conclusions 
The results of this study suggest that not only are side-effects of radiation common in 
HNC patients receiving radiation therapy, but that these side-effects may be associated with 
depression development in this patient population. Care needs to be taken in order to mitigate 
radiation side-effects and to screen for depression in HNC patients undergoing radiation therapy, 
especially those at increased risk for depression development. 
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Table 1. Profile of the study sample by depression status 
  
No Depression  
N=1563 
Depression 
N=196 p-value 
  N % N %   
Age         0.053 
     67-69 399 25.5% 43 21.9%   
     70-74 461 29.5% 71 36.2%   
     75-79 352 22.5% 33 16.8%   
     80-84 209 13.4% 35 17.9%   
     85+ 142 9.1% 14 7.1%   
    
  
    
Gender       <0.001 
     Male 1139 72.9% 115 58.7%   
     Female 424 27.1% 81 41.3%   
    
  
    
Ethnicity        0.153 
 Non-Hispanic white 1266 81.0% 167 85.2%   
Other  297 19.0% 29 14.8%   
    
  
    
Marital vs. Not       0.030 
Not Married/Living as Married 662 42.4% 99 50.5%   
Married/Living as Married 901 57.6% 97 49.5%   
    
  
    
Median Income Census Tract         0.874 
< $35, 000 or Missing 502 32.1% 63 32.1%   
 $35, 000- $44,999 357 22.8% 43 21.9%   
 $45, 000- $59,999 345 22.1% 48 24.5%   
 $60, 000+ 359 23.0% 42 21.4%   
    
  
    
Cancer Site       0.536 
Oral Cavity and lip 263 16.8% 38 19.4%   
Oropharynx 466 29.8% 64 32.7%   
Nasopharynx/Hypopharynx 175 11.2% 21 10.7%   
Larynx 659 42.2% 73 37.2%   
    
  
    
SEER Region       0.123 
Pacific/West 601 38.5% 67 34.2%   
Northeast 329 21.0% 53 27.0%   
Midwest 199 12.7% 30 15.3%   
South 434 27.8% 46 23.5%   
    
  
    
Charlson Comorbidity        0.952 
0 1469 94.0% 184 93.9%   
1+ 94 6.0% 12 6.1%   
    
  
    
Stage       0.097 
Missing/Unstaged 103 6.6% 16 8.2%   
In Situ/Localized 576 36.9% 55 28.1%   
Regional 630 40.3% 86 43.9%   
Distant 254 16.3% 39 19.9%   
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Table 2. Potential radiation side-effects in the study sample by depression status 
  
  
No Depression  
N=1563 
Depression 
N=196 
  
p-value 
  N % N %   
Side-Effects           
Xerostomia          0.799 
No 1457 93.2% 176 89.8%   
Yes 106 6.8% 20 10.2%   
    
   
  
Dysphagia   
   
<0.001 
No 799 51.1% 41 20.9%   
Yes 764 48.9% 155 79.1%   
    
   
  
Aspiration   
   
<0.001 
No 830 53.1% 44 22.4%   
Yes 733 46.9% 152 77.6%   
    
   
  
Dental Caries   
   
<0.001 
No 857 54.8% 47 24.0%   
Yes 706 45.2% 149 76.0%   
    
   
  
Malnutrition   
   
<0.001 
No 792 50.7% 40 20.4%   
Yes 771 49.3% 156 79.6%   
    
   
  
Fatigue or Malaise   
   
<0.001 
No 789 50.5% 41 20.9%   
Yes 774 49.5% 155 79.1%   
    
   
  
Speech Disturbances   
   
<0.001 
No 851 54.4% 46 23.5%   
Yes 712 45.6% 150 76.5%   
    
   
  
Radiation Sickness/Dermatitis   
   
<0.001 
No 847 54.2% 45 23.0%   
Yes 716 45.8% 151 77.0%   
    
   
  
Osteoradionecrosis of Jaw   
   
<0.001 
No 858 54.9% 47 24.0%   
Yes 705 45.1% 149 76.0%   
            
Any Side-Effect         <0.001 
No 642 41.1% 30 15.3%   
Yes 921 58.9% 166 84.7%   
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Table 3. Multivariable analysis of depression diagnosis in HNC patients 
  OR   95%  CI   p-value 
Age            
Ages 67-69 REF 
    
 
Ages 70-74 1.29 
 
0.86 1.94 
 
0.077 
Ages 75-79 0.78 
 
0.48 1.27 
 
0.118 
Ages 80-84 1.37 
 
0.84 2.24 
 
0.077 
Ages 85+ 0.78 
 
0.41 1.50 
 
0.277 
  
     
 
Gender       
Male  REF 
    
 
Female  1.78 
 
1.30 2.44 
 
<0.001 
  
     
 
Ethnicity        
     Non-Hispanic White REF 
    
 
Other 0.70 
 
0.46 1.07 
 
0.097 
  
     
 
Any Side-Effect       
No  REF 
    
 
Yes 3.70  2.47 5.55  <0.001 
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CHAPTER VI 
DISCUSSION AND CONCLUSIONS 
Summary of Current Research 
HNCs are a group of cancers that, although somewhat rare in the United States, appear to 
be highly associated with the psychological health of patients. Individuals with HNC have to deal 
with not only the physical effects of the disease and its treatments, but social, financial, and 
emotional effects of the disease as well (53; 55). Because of the unique ways HNC can affect 
human life, this group of patients may be at increased risk for depression development when 
compared to other cancer sites (49; 51). While previous studies have been conducted to examine 
the psychological effects of HNC more closely, there are still significant gaps in the literature 
regarding the understanding how often HNC patients are afflicted with depression, as well as the 
consequences of this on outcomes. This dissertation sought to help narrow some of the existing 
gaps in the literature and to bring attention to the salient biopsychosocial factors that affect 
patients during HNC development, diagnosis, and treatment. . 
The SEER-Medicare linked database provided an opportunity to explore the relationship 
between depression and HNC in a national, representative sample of older adults diagnosed with 
HNC. This linked databased allowed us to utilize a standard method of identifying both HNC and 
depression diagnoses through diagnostic codes in exiting medical record data. Further, a 
secondary analysis of SEER-Medicare data afforded us the ability to study a large number of 
patients with HNC, which is a relatively rare disease. This data also allowed us to include several 
potential confounding variables that have been identified in the existing literature when 
examining the relationship between cancer diagnosis and depression.  
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Chapter 2 of this dissertation utilized existing literature in order to better understand the 
potential ways in which depression may develop in patients with cancers of the head and neck. 
Previous studies have identified both individual and contextual-level factors that can influence the 
development of depression after cancer diagnosis. Further, based on our review and synthesis, 
there are also individual and contextual factors that can influence depression diagnosis before 
cancer, which may leave individuals at increased risk for HNC. From the resulting conceptual 
model, it can be seen that there are a number of factors that can influence depression in HNC 
patients at all stages. However, most previous literature was based on smaller-scale studies, which 
may not have been representative of the HNC population as a whole. 
Utilizing SEER-Medicare data, Chapter 3 of this dissertation examined the frequency at 
which individuals with HNC are diagnosed with depression. This data allowed the examination of 
over 3,500 individuals from more than 20 locations in the U.S. Based on the study results, some 
form of depression is diagnosed in nearly 19% of HNC patients. Of this group, nearly 11% are 
diagnosed with depression before HNC and an additional 9% develop depression within the first 
year of cancer diagnosis. Additionally, the multivariable analyses showed that those with 
depression had greater odds of being diagnosed with distant stage HNC and those who developed 
depression were diagnosed with later stage of cancer at the time of diagnosis. Chapter 4 further 
studied one segment of the sample from Chapter 3 and examined the potential effect that 
depression diagnosis may have on the survival of HNC patients. The results of Chapter 4 clearly 
showed that individuals diagnosed with depression had significantly poorer survival when 
compared to individuals who received no diagnosis of depression during the study period.  
The final study of this dissertation focused on a sub-group of the patient sample from 
Chapter 4. In this chapter, the potential side-effects of radiation in HNC patients were examined 
in relation to depression development within the first year of cancer diagnosis among those 
without pre-existing depression.   The results of the Chapter 5 study indicate that HNC patients 
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experiencing side-effects of their radiation treatments may be a greater risk for depression 
diagnosis than those who do not experience side-effects. Together, the studies from these chapters 
offer new insight into the relationship between depression and HNC.  
Implications of Current Research 
The findings of this dissertation have extensive clinical implications. The results of all 
studies from this dissertation emphasize the notion that HNC is both a physically and emotionally 
traumatic diagnosis, and that healthcare workers, family members, and patients need to be 
watchful of the potential signs of depression. Recent guideline adaptations released by the 
American Society of Clinical Oncology and the National Comprehensive Cancer Network 
recommend that all patients who receive a diagnosis of cancer be screened for depression and 
anxiety at their first visit, and at other times during the course of cancer that could result in 
changes in emotional well-being, such as at the beginning of treatment (180; 181). Also 
applicable to the current study population, the US Preventive Services Task Force recommends 
regular depression screening for older adults, utilizing tools such as the Patient Health 
Questionnaire (PHQ) (182).  
Along with screening for depression, Stout et al. discussed the idea of making emotional 
well-being a part of the patient’s model of care and helping them think of emotional health as a 
targeted outcome of their cancer recovery (183). The authors also suggested that educating 
patients about their disease and treatments may be beneficial in reducing unnecessary stress and 
including family and friends in some of the skill building strategies for coping may give added 
support (183). The results of this dissertation show just how common diagnosable depression may 
be in this cancer population. Identifying those who may be at risk for, or dealing with, depression 
is the first step in helping these individual improve their psychological health.  
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In addition to identifying existing depression in the HNC and other cancer population, 
emphasis should also be placed on preventing depression in those individuals without depressive 
symptoms. As has been discussed in this dissertation, depression can afflict patients throughout 
the diagnosis and treatment of cancer. Lydiatt et al. (2013) found that prophylactic use of 
antidepressants can help prevent depression development in HNC patients (71). Healthcare 
workers and patients should consider preventative measures, such as psycho pharmaceutical or 
psychotherapeutic interventions for the prevention of depression, both during and after cancer.  
In addition to prevention and early detection of depression in newly diagnosed cancer 
patients, the results of Chapter 3 also support the notion of HNC screening in those with 
depression. The results of the study indicated that individuals with preexisting depression may be 
at increased risk for later stage HNC at diagnosis. It is possible that these individuals have higher 
risk factors and lower self-care and, therefore, may not seek medical attention during the early 
stages of HNC. Based on these results, it may be beneficial to screen individuals who have been 
diagnosed with depression for HNC, specifically if they engage in other risky behavior related to 
the disease such as alcohol or tobacco use. Screening this higher risk population may help to 
detect HNC at earlier stages, leading to better prognoses and less invasive or extensive treatment. 
Chapter 4 of this dissertation found that survival among HNC patients with depression 
was significantly worse when compared to those without depression. These results give support to 
not only the notion of depression screening but also the need for depression treatment in the HNC 
population. Depression treatments can include psychosocial or pharmacological treatments, and 
both have shown to be effective in cancer populations (180; 184). Further, a study by Lydiatt et 
al. found that prophylactic use of antidepressants may reduce depression development in the HNC 
population (71). Identifying and treating HNC patients experiencing depression, or preventing 
depression development, may improve survival outcomes in this patient population. 
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The results of Chapter 5 of this dissertation found a significant association between 
potential side-effects of radiation treatment and depression, indicating that individuals 
experiencing radiation side-effects may be at greater risk of depression. While a causative 
relationship cannot be assumed given the study methods, healthcare providers may consider 
taking preventative measures before radiation treatment aimed at reducing the risk of side-effect 
development in the HNC population. Additionally, providers should be vigilant of side-effects in 
patients’ treatments with radiation, and screen these patients periodically during treatments in 
order to identify and treat depression, as well as mitigate side-effect symptoms.  
Suggested Future Research 
The work in this dissertation adds to the existing literature on the relationship between 
HNC and psychological health. However, there are still many gaps in the literature on which 
future research in this area should focus. Based on the results of this dissertation, several future 
directions are suggested.  
The second chapter of this dissertation focused on the development of a conceptual 
model for understanding the relationship between depression and HNC, which was based on 
previous peer-reviewed literature. This model, which may help in guiding future research, 
included individual and environmental factors that may influence this relationship between 
depression and cancer in the HNC population. However, many of these same factors may apply to 
other cancer sites in terms of depression diagnosis, especially for other substance abuse-related 
cancers, such as lung or esophageal. To continue to understand the influence depression may have 
on health throughout the life course, future research should include developing conceptual models 
of the relationship between depression and cancer diagnosis, focusing on depression before and 
after cancer diagnosis. 
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The current research found that the prevalence of preexisting depression was relatively 
high in this population, though few studies have examined the potential increased risk of HNC 
based on preexisting depression. Moreover, the results of the study done in Chapter 3 showed that 
individuals with preexisting depression may present with later stage of cancer at the time of 
diagnosis when compared to those without depression. Future research should further examine 
the relationship between preexisting depression and cancer development as a potential avenue for 
prevention of HNC by depression mitigation or early detection of HNC through screening in 
individuals experiencing depression. Experimental studies should focus on implementation and 
evaluation of interventions concentrated on increased awareness of early signs of HNC in high-
risk populations. Future longitudinal cohort studies should further examine the potential risks that 
subclinical and clinical depression may have on stage of HNC diagnosis. 
The results of this dissertation work showed that individuals who received a diagnosis of 
depression had worse survival when compared to those who were never depressed. This may be 
due to a lack of self-care and social support, or the result of an underlying biological mechanism 
related to depression. Unfortunately, given our use of secondary data, we were unable to 
determine the reason for this difference. Future studies should attempt to identify the reason for 
this disparity in survival.  Further, while depression may be present in the HNC population, and 
appears to influence survival outcomes, there is minimal literature on the preferred or 
recommended treatments for depression in this cancer group. Future observational or 
experimental studies should aim to identify the most beneficial treatments for depression in HNC 
patients.  Given the influence that depression may have on survival in these patients, finding 
appropriate depression treatments in the HCN population may help to improve not only quality of 
life, but also survival outcomes.  
Radiation side-effects in HNC patients were found to be associated with depression 
development. However, given the nature of the data used, a temporal relationship between side-
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effects and depression could not be identified. Further, side-effects were based on diagnoses from 
administrative data and selected based on previous literature. Therefore, these do not fully depict 
the potential consequences of radiation treatments received by these patients. Future studies 
should further examine the temporal relationships between radiation side-effect and depression 
diagnosis in order to explain this relationship. Additionally, future observational studies should 
utilize primary data collection and qualitative methods to better understand the potential effects of 
radiation treatment on the physical and psychological health of HNC patients. By collecting data 
prospectively, future observational studies could also identify potential implications that pre-
existing depression might have on patients’ treatment decisions.  In addition to observational 
studies, future experimental studies should try to identify prophylactic measure that can be taken 
in order to ease these side-effects in the HNC population and improve patient quality of life 
during and after cancer treatments, which may help to reduce the incidence of depression during 
treatment.   
Limitations  
This dissertation is a secondary analysis of existing administrative and registry data. 
There are several limitations associated with the use of secondary data for this dissertation 
research. In each study conducted in this dissertation, both depression and cancer diagnoses were 
identified using diagnostic codes from the data. This method of identifying depression does not 
allow for a full understanding of specific criteria that were met for depression diagnosis, and also 
does not give us any indication of the severity of the diagnosis. Additionally, there may be 
misclassification when utilizing administrative data, specifically in the exposure groups of these 
dissertation studies. Future studies should work to utilize alternative methods for identifying 
subclinical and clinical depression in the HNC population.  
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In addition to the limitations presented by the identification of diagnoses, the data used 
for this dissertation offers minimal information on any social support or social aspects of the lives 
of these individuals. Because the nature of this dissertation research focuses on the psychological 
aspects of HNC, the social lives of these patients, the support they receive, and the individuals 
with which they may interact can significantly influence the study design and results. Each of the 
studies conducted as part of this dissertation would benefit from having additional information 
about the social aspects of these patients’ lives. Future research should strive to collect more 
detailed information on received and perceived social support in these patients, as well as 
information on their social networks.  
In addition to the lack of information on severity of depression and social aspects of 
patients’ lives, there is also a dearth of information in data concerning depression treatments for 
these individuals. While SEER-Medicare does offer access to Part D files, thereby giving some 
information about psychopharmaceutical treatments received by these patients, these files were 
not available for all years of our study and therefore could not be explored in full. Further, SEER-
Medicare offers minimal information on use of other psychological treatments such as behavioral 
therapy. As a result, the effectiveness of treatments received by these patients could not be 
examined. Future observational and experimental studies should attempt to identify treatments 
received by these individuals as well as the effectiveness of these in the HNC population.  
Conclusions 
Based on the results of this dissertation, approximately one in five HNC patients will also 
be diagnosed with depression, which can affect the quality of life and outcomes of this cancer 
population. Screening for depression throughout the course of cancer, mitigation of treatment 
side-effects, and identifying appropriate depression treatments are all crucial to improving the 
psychological health and survival of the HNC population. 
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